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ABSTRACT 
Bacillus subtilis is a probiotic bacterium that can protect against the murine-
specific attaching and effacing (A/E) pathogen Citrobacter rodentium. C. rodentium 
displays many features observed with the human pathogen enteropathogenic E. coli 
(EPEC). Protection by B. subtilis is mediated by exopolysaccharide (EPS), which is 
encoded by the epsA-O operon that contains 15 genes.  Disruption of one of these genes, 
epsH, which appears to encode a putative glycosyltransferase, leads to the loss of 
protective capacity by B. subtilis and by EPS. EPS is a major component of the B. subtilis 
biofilm and the ΔepsH mutant is unable to form a biofilm. The goal of this project was to 
characterize EPS produced by B. subtilis with mutations to the 15 genes of the epsA-O 
operon and assess how single deletions to the genes affect phenotype (biofilm formation), 
and the capacity to protect mice from disease caused by C. rodentium. We found that 
mutations in 13 of the 15 genes eliminated the probiotic activity of B. subtilis, even 
though some of the mutants developed biofilms. Our goal is to compare the structures of 
EPS from protective and non-protective mutants, and identify a small molecule that can 
be used as a therapeutic to prevent disease caused by enteropathogens. 
. 
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CHAPTER ONE 
REVIEW OF LITERATURE 
The immunomodulatory benefits from interactions of the immune system with 
commensal bacteria in the intestine have long been appreciated (Shanahan 2002). The 
gastrointestinal tract (GIT) is colonized by upwards of 1013 to 1014 bacteria, with the 
majority of bacteria residing in the colon. Bacteria in the GIT provide the host with 
nutrients, extract calories from host food, and modify the host immune system to help 
maintain a state of homeostasis (Guarner and Malagelada 2003; Hardy et al. 2013; 
Hooper, Littman, Macpherson 2012). Bacteria provide these benefits through production 
of a variety of molecules, including polysaccharides, such as polysaccharide A (PSA) of 
Bacteroides fragilis, which interacts with the host and induces mucosal tolerance 
(Mazmanian et al. 2005). Bacterial carbohydrates, such as PSA from B. fragilis, can be 
complex and contain several different sugars linked by glycosidic bonds. In addition, the 
carbohydrates can differ in glycosidic linkages (α or β), linear or branched structure, and 
degree of polymerization (monomers, oligomers, and polymers), making these 
carbohydrates highly diverse. 
Perhaps nowhere else is the diversity of carbohydrates greater than in the 
substances secreted by bacteria to form a biofilm. Bacterial biofilms, some of which 
adhere to host tissue, are a key structure that provides interaction between host and 
bacteria. Biofilms are comprised of mono- or multi-species bacterial communities 
encased in an extracellular matrix (ECM) 
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(Flemming and Wingender 2010; Guttenplan, Blair, Kearns 2010; Sutherland 2001; Vu 
et al. 2009). Great diversity are found in the different carbohydrate polymers in the ECM 
of bacteria and these structures mediate a high degree of interaction between host and 
bacterial communities (Anderson et al. 2003; Fujimura et al. 2010; Hall-Stoodley, 
Costerton, Stoodley 2004; Jones and Knight 2012; Macfarlane and Dillon 2007). 
Bacterial polysaccharides have also been shown to enhance virulence by allowing 
pathogens to evade the host immune system. Two of the best-studied bacterial 
polysaccharides are polysaccharide A (PSA), produced by Bacteroides fragilis, and 
exopolysaccharide (EPS), produced by Bacillus subtilis, both of which have been shown 
to prevent colitis (Jones and Knight 2012; Jones et al. 2014; Onderdonk et al. 1977; 
Round and Mazmanian 2010; Tzianabos et al. 1993).  
The Gram-positive spore forming soil bacterium B. subtilis, which produces EPS, 
exists either as a unicellular planktonic cell or in a nonmotile aggregate biofilm (Lemon 
et al. 2008). Mature biofilms consist of non-motile cells encapsulated in an ECM, which 
is primarily composed of EPS and poly-N-acetyl-glucosamine (Jones et al. 2014; Roux et 
al. 2015). The undomesticated strain of B. subtilis (NCBI 3610) forms colonies with 
wrinkled architecture on LB agar plates and a pellicle between the air liquid interface 
when grown in liquid medium (Branda et al. 2001; Kearns et al. 2005). Formation of a 
biofilm or pellicle is dependent on the production of EPS, which occurs in the cytoplasm 
of the cell and is secreted by an unknown mechanism. Following secretion, EPS is 
localized in the protein scaffold of the extracellular matrix (Driks 2011; Guttenplan, 
Blair, Kearns 2010). Synthesis of EPS is regulated by the genes encoded in the 15-gene 
epsA-O operon and the tapA-sipW-tasA operon. Once EPS is produced by B. subtilis it is 
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most likely stabilized by repeating amyloid protein, TasA, on the extracellular surface of 
the bacteria. The interaction between EPS and the protein scaffold of TasA and TapA is 
unknown (Driks 2011; Guttenplan, Blair, Kearns 2010; Romero et al. 2011). 
A single oral dose of B. subtilis spores can protect mice from enteric disease 
caused by C. rodentium, and the protective activity is provided by EPS, which is 
composed of mannose (~88%) and glucose (12%) (Jones et al. 2014). B. subtilis spores 
with deletions to epsH, a glycosyltransferase of the eps operon, and EPS isolated from a 
epsH mutant (Jones and Knight 2012; Kearns et al. 2005; McLoon et al. 2011), are 
unable to protect from this disease and do not form a biofilm (Jones and Knight 2012). 
The goal of this study was to characterize EPS produced by B. subtilis mutants of the 15 
gene epsA-O operon and to determine which genes are required for biofilm formation and 
which are required for protection from disease caused by C. rodentium. 
 
Gut Host Microbe Interaction 
The microbiome or microorganisms that naturally colonize the host cover the skin 
and gastrointestinal tract (GIT) and are believed to have become resident microbes during 
years of co-evolution (Chung et al. 2012; Hardy et al. 2013; Ley, Peterson, Gordon 2006; 
Macfarlane and Dillon 2007; Madan et al. 2012; Nowrouzian et al. 2003). In exchange 
for an environment favorable for their growth, host microbes provide nutrients, extract 
calories from food, shape the immune system, impact development of allergies, aging, 
mood, and alter susceptibility to disease (Bravo et al. 2011; Hardy et al. 2013; Horton et 
al. 2015; Thorburn et al. 2015; Wu et al. 2010). 
! ! !
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The human microbiome has considerable species diversity and includes the 
genera Bacteroidetes, Actinobacteria, and Firmicutes. As humans age, there are changes 
to the microbial populations in the GIT. The microbiota composition fluctuates over the 
lifetime of its host due to changes in environment, diet, and infection (Gareau, Sherman, 
Walker 2010; Li, Bihan, Methé 2013; Martínez et al. 2015; Saraswati and Sitaraman 
2014). 
The diet of the host provides a way for bacteria to be introduced to the GIT and 
influences the health of the host. Foods rich in metabolites such as butyrate, a short chain 
fatty acid, serve as a source of energy for host colonic epithelial cells, and regulate 
mucosal gene expression, differentiation and apoptosis (Kelly et al. 2015). These foods, 
or prebiotics, also play a role in priming the environment to be favorable for certain 
species of bacteria. On the luminal surface of epithelial cells in the GIT, continuous 
layers of mucus are secreted from goblet cells. This coating of mucus is between 100-
200µm thick and protects against adhesion and invasion by harmful bacteria. Often, 
mucus secreted by the host has complex carbohydrate structures and can only be 
degraded by several hydrolytic enzymes usually sourced from multiple bacteria 
(Macfarlane, Bahrami, Macfarlane 2011; Resta-Lenert and Barrett 2003). Mucins, or 
heavy molecular weight proteins that coat surface epithelial cells, are extensively 
glycosylated, constitutively secreted by goblet cells, and their polymerization provides a 
structural foundation for mucus (Hardy et al. 2013). Colonization with certain bacteria, 
such as Lactobacillus rhamnosus and Lactobacillus plantarum 299v, can up-regulate 
mucin production, thereby preventing attachment by enteropathogens, such as E. coli 
O157:H7 (Curtis et al. 2014; Mack et al. 1999). In addition, species previously thought to 
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exert negative effects on the host, such as Helicobacter pylori, have begun to be 
appreciated for their potential benefits. Recent data on the relationship between H. pylori, 
thought to be responsible for peptic ulcer disease, noncardia gastric cancer, and 
esophageal cancer, may also afford protection against esophageal adenocarcinoma, 
allergic asthma and inflammation, rhinitis, and atopy (Blaser and Atherton 2004; Blaser 
2008; Macfarlane, Bahrami, Macfarlane 2011; Qiu et al. 2011; Reibman et al. 2008). 
Due to the huge diversity of the microbiota, it is difficult to identify which 
bacteria are key players in immunomodulation. To better understand the species and 
mechanisms on host immunomodulation and immune system development, germ-free 
animals, or animals previously unexposed to microorganisms, are used. A benefit to these 
animals is that they limit the diversity of the microbiota and provide some degree of 
control for bacteria that are introduced to a host (Macpherson and Harris 2004; 
Tlaskalová-Hogenová et al. 2011). Once individual species of interest are identified they 
can be isolated and used for individualized treatments which can serve as an attractive 
alternative to conventional therapies and pharmaceuticals (Macfarlane, Bahrami, 
Macfarlane 2011; Thomas, Ockhuizen, Suzuki 2014). The use of beneficial bacteria 
involved in alleviation of disease has already led to improved outcomes for diseases of 
the GIT. Improved outcomes include repression of pathogenic microbial growth, 
prevention of irritable bowel disease (IBD), and prevention of complications from ileal 
pouch-anal anastomosis (IPAA) (Fujimura et al. 2010; Gionchetti et al. 2003; Hooper, 
Littman, Macpherson 2012; Macpherson and Harris 2004; O'shea et al. 2009; Stecher and 
Hardt 2008). 
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Probiotics 
Probiotics, from the Greek ‘pro bios’ (for life), are microbial organisms that 
contribute to human health and are implicated for their potential protective effects against 
inflammatory bowel disease (IBS), antibiotic associated and infectious diarrhea, 
metabolic syndrome, allergic disorders, mood disorders, and cancer (Bravo et al. 2011; 
Gareau, Sherman, Walker 2010; Hume 2011; Wang et al. 2015). These microbes can 
influence the activity of a number of cells of the innate immune system, including but not 
limited to: natural killer T cells, dendritic cells, macrophages, epithelial cells, as well as 
cells of the adaptive arm of the immune system such as Th1 cells, Th2 cells, Th17 cells, 
Treg cells, and B cells (Hardy et al. 2013; Hooper, Littman, Macpherson 2012). Bacteria 
shown to affect these immunomodulatory activities consist of strains from the genera 
Lactobacillus, Bifidobacterium, Bacillus, and Pediococcus (Guandalini 2011; Hardy et al. 
2013; Hume 2011; Wang et al. 2015). Of these genera, only one, Bacillus, displays 
capability to form spores. Spore-producing bacteria can be used as probiotics; spores are 
easy to store and are able to survive the gastric acid of the stomach, successfully 
colonizing the GIT of the host (Hong, Le, Cutting 2005). 
Probiotics have favored niches in the GIT, and these niches are altered when 
changes to the diet are made. In the GIT, ‘functional foods/prebiotics,’ non-digestible 
food ingredients, such as indigestible dietary fiber/carbohydrates, primes the environment 
for probiotics. These non-digestible food ingredients may act cooperatively to selectively 
promote the growth and activity of one or more beneficial probiotic species and stimulate 
activity of pre-existing commensal bacteria (Perez-Vilar and Hill 1999; Roberfroid et al. 
2010; Thorburn et al. 2015). 
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Before the probiotic strains responsible for protection and immune-modulation 
were identified, the protective benefits of fermented and cultured foods had been 
appreciated in fermentation processes throughout history. Fermented and cultured foods 
were present in the Middle East, Ancient Greece and Asia because of their ability to 
alleviate illness and aid human health (Hume 2011); however, their mechanisms of 
protection were not well understood. In 1905, Stamen Grigorov, a Bulgarian 
microbiologist, was the first to identify the potential health benefits of Lactobacillus 
bulgaricus (Lactobacillus delbrueckii ssp. bulgaricus) (Metchnikoff 1908). In 1908, Ilya 
Metchnikoff expanded this finding, developing the hypothesis that human health and 
longevity were associated with the ingestion of lactic acid producing bacteria. Thus the 
first steps leading to a better understanding of how certain foods protect against disease 
was elucidated. 
Metchnikoff reasoned that Bulgarian peasants lived longer and consumed large 
quantities of sour milk containing cultures of what are now known as Lactobacillus 
bulgaricus. In 1954, Werner Kollath proposed the term probiotic to designate “active 
substances essential for healthy development of life” (Guarner and Malagelada 2003; 
Hume 2011). The term was further modified by Lilly and Stillwell in 1965 to describe the 
“substances secreted by one microorganism that stimulate the growth of another” and 
again in 1974 by Parker et. al. to include organisms and substances that contribute to 
intestinal microbial balance (Hume 2011; Soccol et al. 2010). Currently, probiotics are 
identified as live microorganisms which when consumed in adequate amounts, confer a 
health effect on the host (FAO/WHO 2002; Sanders 2008). 
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The term ‘probiotic’ has evolved, but problems with their use persist. Bacteria 
found in commercial products continue to be widely mislabeled, and mechanisms of 
protection are often poorly characterized (Hong, Le, Cutting 2005; Huys et al. 2013; 
Michail et al. 2006; Ngo Thi Hoa et al. 2000; Sanders et al. 2010). Additionally, some 
bacteria labeled as ‘probiotics’ may actually do more harm than no treatment at all 
(Besselink et al. 2008). Future individualized therapies will benefit from a better 
understanding of how probiotics confer protection and identification of which molecules 
are responsible for protection. Additionally, individual molecules are generally easier to 
directly administer over live active cultures (Lemon et al. 2008; Soccol et al. 2010) and 
reduce the risk of potential negative interactions between host and live organisms. 
 
The Extracellular Matrix and Formation of Biofilms 
Biofilms are a key structure in the interaction between the host and bacteria. 
Biofilms are ubiquitous in nature and are comprised of tightly associated mono- or multi-
species bacterial communities that are encased in an extracellular matrix (ECM) 
(Flemming and Wingender 2010). The ECM is a primary component of the biofilm and 
develops over a series of different stages in response to external signals. In early stages, 
planktonic cells congregate at the site of initiation of the biofilm and differentiate into 
non-motile, matrix-producing cells that attach to a surface. These non-motile matrix-
producing bacteria form bundles, grow, and aggregate. When the environment is not 
favorable for the bacterial community, cells lyse or, if they are spore forming bacteria, 
produce spores and the biofilm begins to break down (Flemming and Wingender 2010; 
Vlamakis et al. 2013). 
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The formation of a biofilm is regulated at different stages via diverse 
mechanisms. A well-studied regulatory mechanism responsible for production of a 
biofilm is quorum sensing (QS); the quorum sensing regulatory pathway is known to 
influence production of an ECM. Quorum sensing allows cell-cell communication, 
expression of required genes in a cell-density dependent manner, and the production, 
release, and detection of chemical signaling molecules. There are two QS processes for 
bacteria, autoinducer-1 (AI-1), common in intra-species communication and autoinducer-
2 (AI-2), associated with inter-species interaction (Vu et al. 2009). An example of a QS 
peptide is ComX, which functions as a pheromone and triggers production of surfactin, 
which is involved in mediating a subpopulation of cells to produce an ECM (Marvasi, 
Visscher, Casillas Martinez 2010). However, these are species-specific mechanisms and 
are not necessarily general. Disease-causing bacteria often use the molecules of the ECM 
to facilitate adherence to host tissues, evade detection by the host immune system, and 
prevent phagocytosis (Nwodo, Green, Okoh 2012). 
Molecules of the ECM are not all detrimental to the host, and exopolymeric 
substances secreted by commensal bacteria can actually protect against disease (Jones et 
al. 2014; Mazmanian and Kasper 2006). The best-studied exopolymeric substance is 
polysaccharide A (PSA), one of eight distinct polysaccharides synthesized by the 
commensal B. fragilis. B. fragilis is a Gram-negative obligate anaerobe, and it has a 
capsular polysaccharide complex that co-opts Treg lineage differentiation and induces 
mucosal tolerance (Huang, Lee, Mazmanian 2011; Mazmanian et al. 2005). As 
mentioned previously, EPS from the commensal B. subtilis is also well studied and 
! ! !
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protective against the enteropathogen C. rodentium (D'Arienzo et al. 2006; Hooper et 
al. 2001; McLoon et al. 2011). 
 
Bacterial Polysaccharides and their Immunomodulatory Activities 
Over 99% of microorgansims on Earth live within biopolymers (Rehm 2010; Vu 
et al. 2009). The first discovery of a bacterial polymer dates back to the mid-nineteenth 
century with the discovery of dextran, a microbial polysaccharide in wine, by Louis 
Pasteur. Bacterial polysaccharides are diverse structural products composed of 
glycosidically-linked sugars, and classified as homopolysaccharides or 
heteropolysaccharides. Homopolysaccharides are composed of one monosaccharide in 
repeating units (cellulose, curdlan, dextran, levan, pullulan,) while heteropolysaccharides 
are composed of two or more monosaccharides and are usually present as multiple copies 
of oligosaccharides with three to eight residues (alginate, gellan or xanthan) (Freitas, 
Alves, Reis 2011; Galván et al. 2013; Kumar, Mody, Jha 2007; Öner 2013; Ruffing and 
Chen 2006). 
Bacterial polysaccharides have varying chemical structure and monomer 
composition, as well as physiochemical, and rheological properties. A bacterial 
polysaccharide from one species of bacteria may vary greatly depending on the strain it is 
produced from, making generalizations about the characteristics of polysaccharides 
difficult (Öner 2013). The diverse and unique properties of bacterial polysaccharides 
makes them attractive molecules in food, pharmaceutical, cosmetic, oil drilling, and 
paper manufacturing industries (Rehm 2010; Roca et al. 2015; Schmid, Sieber, Rehm 
2015). The production costs associated with microbial EPS are also high and inhibit use 
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on a wider scale (Freitas, Alves, Reis 2011; Öner 2013; Rehm 2010; Rehm 2015; Roca 
et al. 2015). Most carbohydrate food ingredients used today were introduced between 
1940 and 1965. Some of the best-studied and commercially exploited bacterial 
polysaccharides include alginate, gellan, glucan, guar, hyaluronan, levan, succinoglycan, 
and levan (Freitas, Alves, Reis 2011; Galván et al. 2013; Öner 2013; Ruffing and Chen 
2006). With annual production of bacterial polysaccharides at an estimated 2,000 tons for 
dextran and 100,000 tons of xanthan alone, these bacterial products, their synthesis, and 
their properties are of great value to industry (Rehm 2010). Although bacterial 
carbohydrates are of high importance, their synthesis, physical properties, and structures 
remain poorly characterized. 
Elucidation of the structure and composition of polysaccharides are important 
because minor changes in structure of the polysaccharide can alter recognition between 
host receptor and polysaccharide and the development of disease. Bacteria such as 
Neisseria meningitides, Streptococcus pneumonia, group B streptococci, and 
Staphylococcus aureus all produce forms of capsular polysaccharides that have varying 
levels of virulence. N. meningitides, a gram-negative bacteria, produces multiple 
polysaccharides that are serologically distinct. Of the 13 serogroups produced by N. 
meningitides, six serogroups (A, B, C, W-135, X, and Y) cause disease (Stephens, 
Greenwood, Brandtzaeg 2007; Tzeng and Stephens 2000; Van Kranenburg et al. 1999; 
Zughaier 2011). Understanding how changes to bacterial polysaccharide can reduce 
virulence is of importance for developing targeted therapeutics. Bacterial polysaccharides 
coat the extracellular surfaces of bacteria and contribute to the development of a robust 
extracellular matrix and formation of a biofilm (Guttenplan, Blair, Kearns 2010; McLoon 
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et al. 2011) and are also often necessary for energy storage, adhesion, and immune 
evasion (Kumar, Mody, Jha 2007; Rehm 2010; Schmid, Sieber, Rehm 2015; Sutherland 
2001). Extracellular polysaccharides, such as capsular polysaccharides, are known to 
enhance virulence (Cuthbertson et al. 2009; Nanra et al. 2013; O'Riordan and Lee 2004; 
Stephens, Greenwood, Brandtzaeg 2007) and are implicated in a number of difficult-to-
treat infectious diseases (Djeribi et al. 2012; Hall-Stoodley, Costerton, Stoodley 2004; 
Parsek and Singh 2003; Zegans et al. 2002). 
As mentioned above, the best-studied exopolysaccharides with beneficial 
immunomodulatory activities are PSA, produced by B. fragilis, and EPS produced by B. 
subtilis. EPS produced by B. subtilis, is thought to confer protection through a TLR-4 
dependent pathway. Mice injected with EPS develop increased levels of M2 macrophages 
(ϕ), which are capable of suppressing T-cell proliferation in vitro. It is important to note 
that EPS is not the only bacterial polysaccharide B. subtilis produces. A number of 
neutral polysaccharides add to the structure of the exopolymeric matrix including poly-N-
acetyl glucosamine (PNAG), and type I (β-2,6-linked D-fructose units) and type II 
(fructose and glucose polymer linked by α-glycoside bonds) polymers. Of these bacterial 
polysaccharides produced, Type I and II polymers are synthesized outside the cell by the 
extracellular enzyme levansucrase and are therefore extracellular polysaccharides (Dogsa 
et al. 2013; Marvasi, Visscher, Casillas Martinez 2010; Schmid, Sieber, Rehm 2015). 
Although there are other polysaccharides produced by B. subtilis, EPS and PNAG are the 
primary components of the ECM (Jones et al. 2014; Roux et al. 2015). 
The production of bacterial polysaccharides generally involves multiple 
enzymatic steps with precursor biosynthesis occurring inside the cell and 
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polymerization/secretion localized in the cell envelope. Presently, there are four 
mechanisms known for the production of carbohydrate polymers in bacteria: the 
Wzx/Wzy-dependent pathway, the ATP-binding cassette (ABC) transporter-dependent 
pathway, the synthease-dependent pathway, and the extracellular synthesis pathway used 
by a single sucrase protein. 
 The biosynthesis pathways of polysaccharides are not fully understood and 
different biosynthesis pathways encode multiple types of glycosyltransferases (GTS), 
polymerizing and branching enzymes, and sugar modifying enzymes. The majority of 
cell-surface bacterial polysaccharides are produced from the Wzx/Wzy dependent 
assembly pathway (Islam and Lam 2014). Bacterial polysaccharides from the Wzx/Wzy 
pathway include bacterial surface heteropolysaccharides, such as emulsan produced by 
Acinetobacter lwoffii, succinoglycan produced by Sinorhizobium meliloti, and the type I 
and 4 capsular polysaccharides produced by Escherichia coli. The synthesis of these 
molecules by the Wzx/Wzy dependent pathway begins with individual repeating lipid- 
linked units that are anchored at the inner membrane. The polysaccharide chain grows at 
its reducing end and additions are assembled sequentially by a number of GTS at the 
cytoplasmic face of the inner membrane (IM). Polysaccharides then translocate across the 
cytoplasmic membrane by a Wzx protein, a flippase. Polymerization of the 
polysaccharide is also accomplished by a block transfer mechanism that utilizes the 
polymerase protein, Wzy. The Wzy protein functions at the periplasmic space and 
facilitates the export of the polymer to the extracellular environment where it’s attached 
to the bacterial surface as a capsular polysaccharide (CPS) or released as EPS 
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(Cuthbertson et al. 2009; Freitas, Alves, Reis 2011; Galván et al. 2013; Rehm 2010; 
Schmid, Sieber, Rehm 2015; Yother 2011). 
Most CPS are synthesized by the ABC transporter dependent pathway. 
Polysaccharides are synthesized by GTSs at the cytoplasmic face of the inner membrane 
and depending on the number of GTSs involved, the polysaccharides are either homo or 
heteropolymeric. Transport of synthesized CPCs occurs through tripartite efflux pump 
complexes that span the inner membrane and periplasmatic proteins (Schmid, Sieber, 
Rehm 2015; Whitney and Howell 2013; Willis and Whitfield 2013). 
Arguably a less complicated mechanism is the synthase dependent pathway, 
which results in secretion of completed polymer strands across the membranes and cell 
wall and is independent of a flippase. Polysaccharide polymerization and translocation is 
completed by a single synthase protein and products are generally homopolymeric. Some 
enzymes in the synthase-dependent pathway are bi-functional and perform both 
polymerization and secretion (Schmid, Sieber, Rehm 2015). 
 While a general understanding of the mechanisms for the synthesis of bacterial 
polysaccharides is known, further characterization is necessary to better understand the 
enzymes involved in polysaccharide synthesis. 
 
Glycosyltransferases 
The large variety and complexity of oligosaccharide and polysaccharide structure 
is in part due to the enzymes such as GTSs, glycosidases, glycan phosphorylases, and 
polysaccharide lysases, which synthesize their production. GTSs are a class of enzymes 
that catalyze glycosidic bond formation and utilize sugar donors with a nucleoside 
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phosphate or a lipid phosphate-leaving group (Lairson et al. 2008). There are two 
known classes of GTSs that result in retention (retaining GT) or net inversion (inverting 
GT) at the anomeric carbon relative to the phospho-sugar donor substrate (Gavin, Jon, 
Toone 2009; Lairson et al. 2008). As is true for polysaccharide biosynthesis, the catalytic 
mechanisms of GTS are also poorly understood. Additionally, GTSs vary in their 
substrate specificity and sequence and are classified into two superfamilies on the basis 
of structural fold, GT-A and GT-B. Both GT-A and GT-B GTSs contain Rossman folds 
(Gavin, Jon, Toone 2009; Sánchez-Rodríguez et al. 2014), or structural motifs found in 
proteins that bind cofactors. Incidentally, SpsA, which is produced by B. subtilis, was the 
first GTS shown to adopt a GT-A fold (Lairson et al. 2008). 
 
The epsA-O Operon and Characteristics of EPS 
Genes responsible for the production of EPSs are generally clustered (Dertli et al. 
2013; Van Kranenburg et al. 1999) and identifiable by the multiple GTSs, polymerases, 
and secreting enzymes they encode (Guttenplan, Blair, Kearns 2010; Schmid, Sieber, 
Rehm 2015). EPS is produced by 15 different genes encoded in the eps operon of B. 
subtilis. The 15 genes encoded in the operon have sequences that suggest a variety of 
enzymatic activities including 6 glycotransferases, 2 pyruvyltransferases, as well as a 
kinase, flippase, acetyltransferase, and aminotransferase (Roux et al. 2015). At least one 
of these genes, epsE, encodes for a bifunctional enzyme that promotes matrix synthesis 
and inhibits motility (Guttenplan, Blair, Kearns 2010). 
EPS secreted from B. subtilis with a deletion to epsH, a glycosyltransferase, does 
not inhibit all C. rodentium associated disease markers, or modulate the immune system 
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compared to WT EPS (Jones and Knight 2012; Jones et al. 2014). It is believed that 
epsH is an important enzyme that contributes to the formation of a protective EPS. The 
use of strains of B. subtilis with deletions to the genes of the eps operon is a unique and 
novel approach to identify immunomodulatory forms of a bacterial polysaccharide. 
 
Figure 1. Illustration of the order of the 15 genes of the epsA-O operon. Labels below 
the gene indicate the suggested type of enzyme the gene encodes. Red text is to highlight 
the large number of putative glycosyltransferases found in the operon. 
 
Citrobacter rodentium as a Model of Enteric Disease 
Citrobacter rodentium is a Gram negative (G-) attaching and effacing (A/E) 
mouse specific enteropathogen, previously known as Citrobacter freundii (Luperchio et 
al. 2000; Schauer et al. 1995). C. rodentium induces actin filled membranous protrusions, 
pedestals, at the site of attachment. Following pedestal formation, an A/E lesion forms 
and the pathogen breaches the epithelial barrier infecting the host. C. rodentium is used in 
infection models in mice to study diseases such as enteropathogenic E. coli (EPEC), 
eterohaemorrhagic E. coli (EHEC), Crohn’s, ulcerative colitis (Chandrakesan et al. 2014; 
Higgins et al. 1999). These are diseases that have few prophylactic treatments available. 
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C. rodentium is genetically similar to the human attaching and effacing (A/E) 
pathogens which attach and adhere to the intestinal epithelium, destroy microvilli, 
displace commensal microbiota, and deplete goblet cells. C. rodentium shares 67% of 
genes with EPEC and EHEC (Petty et al. 2010) including the locus of enterocyte 
effacement pathogenicity island (Garmendia, Frankel, Crepin 2005), which encodes 
effector proteins and a type III secretion system. It also expresses many of the same 
effectors of EPEC and EHEC, such as a type IV pilus, which is known to increase 
colonization (Mundy et al. 2003). 
Following infection with C. rodentium, mice develop transmissible murine crypt 
hyperplasia (TMCH), which is accompanied by intestinal inflammation during colitis. 
TMCH is caused by thickening of the colonic mucosa which is a result of excessive 
induction of epithelial regeneration and repair mechanisms (Barker, De Wetering, 
Clevers 2008; Barthold and Jonas 1977; Luperchio and Schauer 2001; Mundy et al. 2005; 
Schauer and Falkow 1993a; Schauer and Falkow 1993b). Mice also develop colitis and 
this contributes to the overgrowth of C. rodentium and an overall reduction of total 
bacterial diversity in the GIT (Mundy et al. 2005). TMCH is triggered by the loss of 
epithelial barrier integrity and the transit of bacteria into the sterile lamina propria. Mice 
with TMCH generally experience cycles of biphasic disease (progressive and regressive 
phases) that last 2-3 weeks (Chandrakesan et al. 2010; Luperchio and Schauer 2001). 
During the progressive phase, fibroblast growth factor 7 and IL-11 are produced by 
pericryptal myofibroblasts. Other uncharacterized signals trigger cell proliferation via 
activation of WNT-β-catenin, signal transducer and activator of transcription3 (stat3), and 
phosphatidylinositol 3-kinase-AKT-β-catenin signaling pathways (Brown et al. 2011; 
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Gibson et al. 2010; Papapietro et al. 2013). The regressive phase involves pathogen 
clearance and resolution of colitis and inflammation and a return to normal intestinal 
homeostasis (Chandrakesan et al. 2010). 
Probiotics including Lactobacillus rhamnosus, Lactobacilus helveticus, and 
Bifidobacterium breve UCC2003 have been shown to prevent C. rodentium colonization 
(Hardy et al. 2013). The gut commensal Bacteroides thetaiotaomicron is thought to 
exacerbate infection and increase gut permeability (Curtis et al. 2014) and contribute to 
worsening of disease. B. subtilis has been shown to prevent symptoms of disease 
(D'Arienzo et al. 2006; Mazza 1994) and it is now believed that EPS produced by B. 
subtilis is responsible for protection against C. rodentium associated disease (Jones and 
Knight 2012; Jones et al. 2014). Interestingly, protection by EPS is independent of 
colonization levels of C. rodentium suggesting that EPS modulates the immune system of 
the host (Jones and Knight 2012). 
 
Methods for the Analysis and Study of Complex Carbohydrates 
 Bacterial polysaccharides can be extremely large and vary in molecular weight (a 
few thousand to several million Daltons), and their study requires a unique set of methods 
(Cui 2005; Kumar, Mody, Jha 2007). Carbohydrates are heterogeneous and differ in their 
primary structure, charge, linkages (α- and β-) and degree of polymerization, and have 
macromolecular characteristics including linear and branching structure. These variations 
give polysaccharides a number of properties and makes their study difficult. 
Successful analysis of polysaccharides relies on the removal of other substances 
that interfere with analysis and results are influenced by how the sample was prepared. 
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Low molecular weight carbohydrates can be extracted with hot 80% ethanol while 
water-soluble polysaccharides can be precipitated with >70% ethanol and a low molarity 
salt solution (Benhura and Chidewe 2011; Cui 2005; Davis and Clapp 1961; Eliasson 
2006; Healey et al. 2014; Nielsen 2010; Smidsrod and Haug 1967; Weising et al. 2005). 
 Much of what is known about bacterial carbohydrates comes from their use in 
industry (Vu et al. 2009; Walt et al. 2012). Xanthan gum, produced by the bacterium 
Xanthomonas campestris, is a unit-repeating polymer and is most likely the best-studied 
extracellular polysaccharide. This high molecular weight (3x105-8x106 Da) bacterial 
polysaccharide is used in industry and agribusiness and valued for its solubility in either 
hot or cold solutions, high viscosity at low concentrations, and cellulose-like backbone. 
Although it was cleared for use by the FDA in 1969 and its synthesis has been 
extensively studied, the polymerization and export of xanthan is poorly characterized as 
is the biosynthesis of other bacterial polysaccharides (Cui 2005; Galván et al. 2013; 
Hassler and Doherty 1990; Kumar, Mody, Jha 2007; Roca et al. 2015). 
 Basic analysis has historically been limited to the presence or absence of 
carbohydrate in a sample. Assays such as the phenol-sulfuric acid assay (Dubois et al. 
1956) and the anthrone assay are two tests used to determine the presence of 
carbohydrate content; however, phenol-sulfuric acid assays are more commonly used 
(Nielsen 2010). In the presence of a strong acid and heat, carbohydrates undergo a series 
of reactions that lead to the formation of furan derivatives such as furnanaldehyde and 
hydroxymethyl furaldehyde. A dehydration reaction is followed by newly formed furan 
derivatives which condense with themselves and phenolic compounds if present, and 
produce dark colored complexes which can then be measured at 490nm (Nielsen 2010). 
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Although useful in detecting carbohydrate in a sample, any measurement of the total 
sugar is an estimate based on the reactivity of the sugar used as a standard (historically 
glucose) and many different sugars in solution react differently with the assay reagents 
(Cui 2005; Nielsen 2010). Additionally, samples can be assayed for the presence of a 
carbohydrate via a modified phenol sulfuric acid assay which does not use a phenol 
solution and therefore reduces reagents and chemical interaction (Albalasmeh, Berhe, 
Ghezzehei 2013). There are also enzymatic methods of analysis but these methods 
require a basic knowledge of the polysaccharide composition (Gawehn 1988). 
 Presently, advances in the field of carbohydrate analysis have created a number of 
new methods that enable the determination of the structure of complex polysaccharides. 
These include fast atom bombardment mass spectrometry (FAB-MS), matrix-assistant 
laser desorption ionization mass spectrometry (MALDI-MS), electrospray ionization 
mass spectrometry (ESI-MS), nuclear magnetic resonance (NMR) spectroscopy, 
Correlation Spectroscopy (COSY), Total Correlated Spectroscopy (TOCSY), and 
Distortionless Enhancement by Polarization Transfer (DEPT). All of these techniques 
allow for the solving of structure and composition with some being more precise than 
others. A problem that persists is that these methods require specialized equipment and 
reference databases that are not always available (Bubb 2003; Cui 2005; Walt et al. 
2012). NMR is presently one of the most powerful techniques for carbohydrate analysis. 
Use of NMR in conjunction with other analytical methods allows for a characterization of 
a complex polysaccharide including detailed structural information of carbohydrates, 
identification of monosaccharide composition, elucidation of α- or β- anomeric 
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configurations, establishment of linkage patterns, and identification of large polymer 
sugar units in oligosaccharides and/or polysaccharides (Bubb 2003; Cui 2005). 
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CHAPTER TWO 
MATERIALS AND METHODS 
Pellicle and Biofilm Formation Assays 
To assess pellicle formation of B. subtilis mutants, overnight (O/N) bacterial 
starter cultures were diluted 1:100 in a total volume of 2mL per well in a 24-well tissue 
culture dish and incubated without agitation for 24 hr at 37°C. Following incubation, 
pellicle formations at the air-liquid interface were assessed with bright field microscopy 
and photos taken. 
To assess biofilm formation, O/N bacterial starter cultures were diluted 1:100 and 
25µL was plated onto plates containing Luria-Bertani (LB) media (Difco) with 1.5% agar 
(Beckman Dickinson). The plates were incubated without agitation for 24 hr at 37°C. 
Biofilm formation was assessed with bright field microscopy and photos taken. Strength 
of biofilm formation was quantified by microtiter dish biofilm formation assay as 
described by O’Toole (O'Toole 2011). Briefly, 100µL of a 1:100 dilution of starter 
culture was plated and incubated for 16 hr. Plates were washed twice with water and 
125µL of a 1% crystal violet (CV) solution was added to wells and incubated at room 
temperature (RT) for 20 min. Plates were washed with deionized water (dH2O) four times 
and 150µL of a 30% acetic acid solution was added to wells of the microtiter plate to 
solubilize remaining CV. The 150µL of solubilized CV was then transferred into a new 
flat-bottomed microtiter dish and the absorbance of the liquid measured at 550nm. 
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Purification of EPS 
To isolate and purify EPS produced by B. subtilis mutants, 10mL of LB broth was 
inoculated from a frozen glycerol stock and incubated for 16 hr at 250 RPM at 37°C. A 
1:1000 dilution of bacterial starter cultures was made in 1L of LB broth and incubated for 
16 hr at 37°C. Cultures were pelleted at 4500 x g for 20 min at RT and the supernatant 
collected. Supernatants were precipitated with 50% ethanol (EtOH) and incubated O/N at 
-20°C. Precipitates were pelleted at 15000 x g for 20 min at 4°C, re-suspended in 100mL 
of 0.1M Tris, and treated with DNase (67µg/mL) and RNase (330µg/mL) for 4 hr at 
37°C. DNase and RNase digested samples were digested with Proteinase K (40 µg/mL) 
for 4 hr at 56°C and precipitated with 100mL 50% EtOH and incubated O/N at -20°C. 
Precipitates were pelleted at 15000 x g for 30 min at 4°C. 
EPS pellets were re-suspended in 0.1M Tris with a working concentration of 
sodium azide and loaded on a size exclusion column with a Sepharcryl 1000 (allyl 
dextran and N,N’-methylene bisacrylamide) matrix. Fractions containing EPS were 
identified by a modified phenol sulfuric acid assay as described in Albalasmeh et. al. 
(Albalasmeh, Berhe, Ghezzehei 2013). Briefly, 30µL of fraction sample volume was 
added to a 96-well microtiter dish and 90µL of concentrated H2SO4 (18M) was added to 
wells. Microtiter dishes were then placed on the surface of a water bath set at 68°C for at 
least 30 min and the absorbance measured at 315 nm on a UV-Vis Spectrophotometer 
(BMG Labtech, Omega SPECTROstar). 
Phenol sulfuric acid assay positive fractions were pooled and precipitated with 
50% EtOH and incubated O/N at -20° C. Precipitates were collected at 15000 x g, re-
suspended in tissue culture grade water and dialyzed O/N at 4°C in 1L of tissue culture 
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grade water. Dialysis cassettes (Life Technologies, Slide-A-Lyzer) with a molecular 
weight cut off of 10K were used to remove small impurities, salts, and remaining sodium 
azide in EPS samples. Dialyzed samples were precipitated with 50% EtOH O/N at -20°C. 
Precipitates were collected at 12500 x g for 20 min at 4°C and dried in a vacuum 
centrifuge. 
Purified EPS from B. subtilis strains used in this study were re-suspended in 0.1M 
Tris or 1X phosphate buffered saline (PBS). 
 
10X PBS 
NaCl 2.99 M 
NaH2PO4 37    μM 
Na2HPO4 168  μM 
        pH to 6.45 
 
 
Comparison of EPS Size Isolated from Bacillus subtilis Mutants 
To assess the size of pre-column purified EPS from various B. subtilis mutants, 
100µL of 50µg/mL EPS was loaded into a fast performance liquid chromatography 
(FPLC) apparatus (GE, AKTA protein purification system) with a Superose 6 (agarose 
matrix) 10/300 GL Size Exclusion Tricorn column (GE). Solutions of 20mg/mL Blue 
Dextran (>2,000KD), 6mg/mL apoferritin (450kD), 6mg/mL IgG (150kD), and a 10M 
fructose were also loaded on the column to serve as reference points of size. 
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Detection of Similar Epitopes of EPS Isolated from Various Bacillus subtilis 
Mutants 
To assess if EPS isolated from B. subtilis mutants had similar epitopes to WT 
EPS, modified western SDS-PAGE was performed. Samples of pre-column EPS were 
prepared as described previously and samples were boiled for 10 min at 95°C. A 5% 
stacking gel and 10% resolving gel were prepared and a total volume of 30µL was loaded 
onto a western SDS-PAGE apparatus consisting of 5µL of 6X sample buffer, and 25µL 
of a 1mg/mL sample of EPS. EPS samples were run at 100 Volts (V) for 1.5 hr and 
transferred to nitrocellulose membrane (LifeTechnologies) O/N at 100mA at 4°C. Free 
binding sites on nitrocellulose membranes were blocked with 5% skim milk in 1X TBST 
for 2 hr and incubated with a 1:10000 dilution of 1mg/mL primary rabbit anti-EPS serum 
Ab in 1X TBST with 5% bovine serum albumin (BSA). Nitrocellulose membranes were 
treated with a 1:10000 dilution of a 1mg/mL secondary horseradish peroxidase-
conjugated goat anti-rabbit IgG (LifeTechnologies) in 1X TBST with 5% BSA for 30 
min Immunoblots were developed using Immun-Star HRP (BioRad). 
 
EPS Binding to Peritoneal Cells 
To assess the level of binding of EPS from B. subtilis mutants to macrophages 
(MΦ) isolated from the peritoneal cavity, cells from the peritoneal cavity were analyzed 
by flow cytometry using a BD FACSCanto II flow cytometer. Approximately 2 million 
cells were collected from C57Bl/6 mice by peritoneal lavage and red blood cells lysed by 
a 5 min incubation with ammonium-chloride-potassium (ACK) Lysing Buffer 
(LifeTechnologies). Cells were washed once in 1mL of FACS buffer, 1X PBS, 10% Fetal 
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Calf Serum (FCS), and pelleted by centrifugation at 300 x g for 5 min. Pellets were re-
suspended in a volume of 100µL FACS buffer. One µL of 1mg/mL EPS was added to the 
cells and incubated for 30 min at 4°C. Samples were washed with 2mL FACS buffer and 
the pellet re-suspended in 100µL. One µL of 1mg/mL rabbit anti-EPS serum Abs was 
added to samples and incubated for 30 min at 4°C. Cells were washed with 1mL of FACS 
buffer and the pellet re-suspended in 100µL. Cells were stained for the presence of 
macrophage markers with 1µL of a 1mg/mL rat anti-mouse F4/80 (BioLegend, Catalog 
#123117) MΦ marker conjugated to allophycocyanin (APC) and 1µL of a 1mg/mL goat 
anti-rabbit IgG Ab conjugated to fluorescein isothiocyanate (FITC) (Lifetechnologies, 
Catalog#65-6111), and incubated for 30 min at 4°C. Tubes were washed with FACS 
buffer and the pellet re-suspended in a final volume of 300µL of FACS buffer. Samples 
were analyzed by flow cytometry using the BD LSRFortessa or BD FACSCanto II flow 
cytometers; data were analyzed by the Flow Jo flow cytometry program.  
 
Polysaccharide Composition Enzyme Assay 
To identify the monosaccharide composition of EPS produced by B. subtilis 
mutants, EPSs were assayed for percentage of D-mannose, D-Fructose, and D-Glucose as 
described with slight modifications by Gawehn et. al. (Gawehn 1988). Briefly, 30µL of 
10mg/mL EPS was treated with 4M trifluoroacetic acid (TFA) for 18 hr at 95°C 
(Biermann 1988; Fengel and Wegener 1979; Galanos, Lüderitz, Himmelspach 1969). 
Samples were dried and re-suspended in 10µL of 0.1M Tris. Enzyme reactions were 
carried out in a 200µL total reaction volume. In a 96-well micotiter dish, 188µL of 
45.6mM triethanolamine buffer (TEA), 2µL of 3µg/µL EPS, 2µL of 0.55mM adenosine 
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tri-phosphate (ATP), 2µL of 0.36mM nicotinamide adenosine-di-phosphate (NADP), 
and 2µL of 4.6U/mL hexokinase was added to each well and measured for base 
absorbance at 340 nm. 
 
TEA$Buffer$
Triethanolamine! 45.6  mM!
MgCl2! 6.4    mM!
β-Mercaptoethanol 1.3    mM!
 
 
Enzyme preparations of 2µL 0.9U/mL of Glucose-6-Phosphate Dehydrogenase 
(G6PDH), 2µL of 2.3U/mL Phosphoglucose Isomerase (PGI), and 2µL of 4U/mL 
Phosphomannose Isomerase (PMI) was added in succession and incubated at RT for 20 
min, 10 min, and 30 min respectively and absorbance measured at 340 nm at each step. 
 
 
Figure 2. Illustration of the enzymatic reactions in a monosaccharide composition 
assay. HK – Hexokinase, G6P-DH – Glucose-6-Phosphate Dehydrogenase, PGI – 
Phosphoglucose Isomerase, PMI – Phosphomannose Isomerase  
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Mice 
All animal experiments were performed according to protocols approved by the 
Institutional Animal Care and Usage Committee at Loyola University Medical Center, 
Maywood, IL. C57BL/6 founders were from Charles River Laboratory (Wilmington, 
MA), and mice utilized for experiments (4 to 6 weeks of age) were bred at Loyola 
University, Chicago, IL. Sterile standard chow and tap water were given to mice ad 
libitum. 
 
Bacterial Strains and Spore Preparation 
The 32 B. subtilis strains used in this study were provide by Dr. Daniel Kearns 
(Indiana University, Bloomington, IN) and are as follows: wild-type NCBI 3610, 
DK1943 (ΔepsA), DK1806 (ΔepsB), DK1807 (ΔepsC), DS4248 (ΔepsD), DS2152 
(ΔepsE), DS4164 (ΔepsF), DS7499 (ΔepsG), DS6776 (ΔepsH), DK1758 (ΔepsI), 
DS4166 (ΔepsJ), DK2055 (ΔepsK), DS7432 (ΔepsL), DS4901 (ΔepsM), DS4900 
(ΔepsN), DK1759 (ΔepsO), DK1960 (ΔepsA ΔsinR ΔtasA), DK1821 (ΔepsB ΔsinR 
ΔtasA), DK1822 (ΔepsC ΔsinR ΔtasA), DK7724 (ΔepsD ΔsinR ΔtasA), DS2369 (ΔepsE 
ΔsinR ΔtasA), DS7722 (ΔepsF ΔsinR ΔtasA), DS7760 (ΔepsG ΔsinR ΔtasA), DS7148 
(ΔepsH ΔsinR ΔtasA), DK1781 (ΔepsI ΔsinR ΔtasA), DS7723 (ΔepsJ ΔsinR ΔtasA), 
DK2057 (ΔepsK ΔsinR ΔtasA), DS7761 (ΔepsL ΔsinR ΔtasA), DS7726 (ΔepsM ΔsinR 
ΔtasA, DS7725 (ΔepsN ΔsinR ΔtasA), DK1782 (ΔepsO ΔsinR ΔtasA) and were 
generated as described by Kearns et. al. (Kearns et al. 2005). Briefly, strains of B. subtilis 
mutants were generated using insertion deletion with long flanking homology PCR and 
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transformed into competent cells of B. subtilis strain PY79 and transferred to B. subtilis 
strain 3610. 
B. subtilis spores were generated via exhaustion (Monteiro et al. 2005). Briefly, 
O/N bacterial starter cultures were diluted 1:100 in Difco sporulation medium (DSM); 
 
Difco Sporulation Medium (DSM) – per liter 
Bacto nutrient broth (Difco) 8       g 
10% (w/v) KCl 10     mL 
1.2% (w/v) MgSO4 • 7H2O 10     mL  
NaOH, pH 7.6 1.5    µM  
Ca(NO3)2 1       µM 
MnCl2 0.01  µM 
FeSO4 1       µM 
 
 and incubated for 48 hr 250 RPM at 37°C. Bacteria were pelleted at 5000 x g for 15 min 
at 4°C and washed three times in ice-cold sterile water. Pellets were re-suspended in 
sterile water and heat shocked at 68°C for 30 min to kill any remaining vegetative cells. 
Samples were washed three times with ice-cold water and stored at 4°C. Spore 
preparations were assessed for spore concentrations by culturing serial dilutions. On the 
day of administration, 109 CFU B. subtilis spores were washed with ice-cold sterile water, 
re-suspended in 200µL 1X PBS, and given to mice via oral gavage (o.g.). 
For infection studies, C. rodentium ATCC 51459 was cultured for 16 hr in LB 
media, washed once in 1X PBS and an infectious dose of 5X108 CFU was re-suspended 
in 200µL of sterile PBS for administration to mice by o.g. 
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Isolation and Identification of Bacteria Contained in Natto 
Three brands of Natto (soybeans fermented with B. subtilis), Hiruzen (Natto 1), 
Marukin (Natto 2), and Mizkan (Natto 3), were obtained from a local grocery store, 
diluted in LB media and particulates removed. Samples were heat shocked for 45 min at 
70°C and plated on LB media with 1.5% agar. Single colonies were selected and 
analyzed using matrix assisted laser desorption ionization – time of flight mass 
spectrometry (MALDI-TOF MS) (Bruker Daltonik Maldi Biotyper). Sample time of 
flights were measured against clinical and research databases and scored for match to 
most likely bacterial species (Bruker Research Database). 
 
Citrobacter rodentium Disease Model 
 Specific-pathogen-free C57Bl/6 mice were orally administered B. subtilis spores 
(109 in 200µL in 1X PBS) 24 hr prior to infection with 5X108 CFU of C. rodentium by 
o.g. Age- and gender- matched mice were utilized for each experiment. To assess disease, 
mice were euthanized 10-11 days post infection and tissues collected. Mouse feces were 
collected and scored for degree of diarrhea. Fecal samples were scored as described 
(Jones and Knight 2012) using a scale from 1 to 4 with a score of 1 = no diarrhea; 2 = 
slightly soft stool - mild diarrhea; 3 = very soft stool - moderate diarrhea; 4 =unformed 
stool - severe. 
 To measure colonization with B. subtilis, feces were homogenized in 500µL of 
sterile 20% glycerol in 1X PBS, and serial dilutions were cultured on selective LB with 
1.5% bacto agar to determine the total number of B. subtilis CFU. Vegetative cells were 
killed by heating at 68°C for 30 min, and serial dilutions were plated onto LB medium 
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plates to quantify the spores. Plates were incubated overnight at 37°C; the resulting 
colonies are represented as the number of CFU per gram of feces. 
 To measure colonization by C. rodentium, feces taken 10-11 days post infection 
were homogenized in 500µL of sterile 20% glycerol in 1X PBS, and serial dilutions were 
cultured on selective MacConkey agar plates. Plates were incubated overnight at 37°C, 
and only small colonies that displayed the characteristic pink center surrounded by a 
white rim were counted. The level of colonization was calculated and expressed as the 
number of CFU per gram of feces. 
 To assess for C. rodentium induced colonic alterations, distal colons from 
euthanized mice were collected and fixed overnight in 10% formalin-buffered phosphate, 
embedded in paraffin and hematoxylin and eosin (H&E) stained. Longitudinal tissue 
sections were examined for epithelial hyperplasia and goblet cell loss with bright field 
microscopy and photos taken. 
  
 
Figure 3. Model of C. rodentium infection. 
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Serum Inflammatory Chemokine ELISA 
 To assess the level of serum inflammatory keratinocyte chemoattractant (KC) 
cytokine, enzyme-linked immunosorbent assays (ELISA) were performed. Mictrotiter 
plates (96-well) were coated with 100µL of a 2.0µg/mL mouse KC capture antibody 
(R&D Systems, Catalog #DY453, Part #840325) and incubated overnight at 4°C. Plates 
were washed with ELISA washing buffer (0.05% Tween20 in 1X PBS) three times and 
free binding sites blocked with 300µL of a 1X reagent diluent (R&D Systems, Catalog 
#DY995) and incubated for 1.5 hr at RT. Plates were washed three times and 100µL of 
serum samples and standards were added and incubated for 2 hr at RT. Plates were 
washed three times and 100µL of a 200ng/mL biotin labeled rat anti-mouse KC detection 
Ab in carbonate buffer (R&D Systems, Catalog #DY453, Part#840326) was added and 
incubated for 2 hr at RT. Plates were washed three times and 100µL of a 200ng/mL 
Streptavidin-HRP reagent (R&D Systems, Catalog #DY453, Part #893975) was added 
and incubated at RT for 30 min. Plates were washed three times and 100µL of a working 
concentration of 3,3’,5,5’-tetramethylbenzidine (TMB) (LifeTechnologies, Catalog #00-
2023) was added and the absorbance measured at 405 nm. Concentrations of KC were 
calculated against a standard solution of recombinant mouse KC (R&D Systems Catalog 
#DY453, Part #840327). 
 
Carbonate Buffer 
Na2CO3 15    µM 
NaHCO3 34.5 µM 
           pH 9.5 
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Allergic Sensitization to Ovalbumin  
 To assess sensitization to ovalbumin, C57Bl/6 mice were orally gavaged with 109 
CFU of B. subtilis spores at day -3, and -1. At day 0, mice were injected intraperitoneally 
(i.p.) with 100µL ovalbumin (100µg/mL) in 1X PBS (OVA) (SIGMA Fraction V) and 
100µL of 20mg/mL alum in 1X PBS (Thermo Scientific Catalog #77161, Lot 
#OD182171). Blood from sensitized mice was collected at day 14 and sera was assessed 
by ELISA for levels of IgG1 and OVA-specific IgG1. 
 
 
Figure 4. Model of allergic sensitization to ovalbumin. 
 
 
 To measure levels of total IgG1 from sera of sensitized mice, 96-well microtiter 
plates were coated with 100µL of a 2µg/mL rat anti-mouse IgG1 primary antibody in 
carbonate buffer and incubated O/N at 4°C. Plates were washed three times with ELISA 
washing buffer, blocked with 100µL of a 3% BSA in 1X PBS solution, and then 
incubated for two hours at RT. Plates were washed three times and 100µL of a 500ng/mL 
standard diluted in duplicate two-fold six times was added. Serum (100µL of 1:20000) 
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was added and plates were incubated for 1 hr. at RT. Plates were washed three times 
and 100µL of a 2µg/mL biotinylated rat anti-mouse IgG1 secondary antibody 
(BioLegend, Catalog #406604) added and incubated for 1 hr at RT. Plates were washed 
three times and 100µL of a 1:3000 Streptavidin-HRP solution added and incubated in the 
dark at RT for 30 min. Plates were washed three times and 100µL of a working 
concentration of 3,3’,5,5’-tetramethylbenzidine (TMB) added and absorbance measured 
at 405 nm. 
 To measure levels of OVA-specific IgG1 from sera of sensitized mice, 96-well 
microtiter plates were coated with 100µL of 10µg/mL OVA in carbonate buffer pH 9.2 
and incubated O/N at 4° C. Plates were washed three times, blocked with 100µL of 3% 
BSA in 1X PBS and incubated for 2 hr at RT. Plates were washed three times and 100µL 
of serum (1:20,000) was added and plates were incubated for 1 hr. at RT. Plates were 
washed three times and 100µL of a 2µg/mL biotinylated rat anti-mouse IgG1 secondary 
antibody (Biolegend, Catalog #406604) added and incubated for 1 hr at RT. Plates were 
washed three times and 100µL of a 1:3000 Streptavidin-HRP solution added and 
incubated in the dark at RT for 30 min. Plates were washed three times and 100µL of a 
working concentration of TMB added and absorbance measured at 405 nm. 
 
Generation of Bone Marrow Derived Mast Cell (BMDMC) and Peritoneal Derived 
Mast Cell (PDMC). 
 Peritoneal cells from C57Bl/6 mice were collected by peritoneal lavage in 
Roswell Park Memorial Institute media (RPMI) (LifeTechnologies, Catalog #31800) with 
1X RPMI additive and pelleted at 300 x g at 4°C for 5 min. For generation of BMDMCs, 
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femurs and tibias from mice were harvested and bone marrow (BM) collected. Pellets 
were washed once in RPMI and spun at 300 x g at 4°C for 5 min. Pellets were re-
suspended in 5mL cell culture medium (RPMI with additive and 10% FCS) and 
transferred into a small cell culture flask. Cells were incubated at 37°C and 5% CO2. 
 
10X RPMI Additive – per liter 
L-glutamine (200mM) 120 mL 
MEM Vitamin Solution (100X) 100 mL 
Penicillin Streptomycin (10,000U/mL) 50   mL 
Fungizone (250µg/mL) 20   mL 
Non-Ess AA (100X) 100 mL 
ESS AA (50X) 100 mL 
Hepes (1M) 100 mL 
Na Pyruvate (100mM) 100 mL 
7.5% NaHOC3 260 mL 
Gentamicin (50mg/mL) 30   mL 
β-Mercaptoethanol 35   µL 
Tissue culture grade H2O 70   mL 
 
  
On day three, non-adherent cells were discarded and 5mL of medium with 
30ng/mL SCF and 10ng/mL IL-3 was added and placed back into the incubator (37° C, 
5% CO2). At day 6, 5mL of fresh medium was added with 30ng/mL SCF and 10ng/mL 
IL-3 preparations to flasks. Cell cultures were assessed for mast cell purity by flow 
cytometry and stained with FcεRIα and CD117 cell markers. At day 9 or 10, 
approximately 300,000 non-adherent cells were assessed for purity by staining with 
hamster anti-mouse FcεRI (BioLegend, Catalog #134314) in 100µL with 1µL of a 
1mg/mL, rat anti-mouse CD117 (BioLegend, Catalog #105807), and rat ant-mouse 
FcBlock (CD16/32) (BioLegend Catalog #101319). Samples were analyzed by flow 
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cytometry using the BD LSRFortessa or BD FACSCanto II machines; data were 
analyzed by the Flow Jo flow cytometry program. 
To assess the morphology of BMDMC and PDMC, cells were washed in FACS 
buffer and spun at 300 x g for 5 min. To visualize purified BMDMC or PDMCs, 
approximately 200,000 purified cells were washed and suspended in 100µL of 1X 
Tyrode’s buffer. Cells were spun on a glass slide with a cytospin centrifuge and fixed, 
stained with Diff-Quick and morphology visualized on bright field microscopy. 
 
1X Tyrode’s Buffer – per liter 
Hepes 10    mM 
NaCl 129  mM 
CaCl2 1.86 mM 
MgCl2 2.13 mM 
Glucose 5.6   mM 
BSA 1      g 
  
 
Mast Cell Degranulation Assay 
 To assess mast cell degranulation 5mL of approximately 200,000 cells per mL of 
BMDMC or PDMC in RPMI were treated with 5µL of 10mg/mL EPS. Cells were primed 
with 2µg/mL of 1mg/mL IgE anti-DNP at 37°C O/N. BMDMC or PDMC were derived 
as described previously. Cells were washed in 1X Tyrode’s buffer and spun at 1000 RPM 
at (RT) for 5 min. Pellets were re-suspended in 100µL of 1X Tyrode’s buffer and 10µL 
added in duplicate to a 96-well V-bottom plate. Serially diluted (20,000ng/mL, 
2,000ng/mL, 200ng/mL, 20ng/mL and 2ng/mL) 2,4-dinitrophenol (DNP) were added to 
each sample (10µL) and incubated at 37°C for 60 min. Plates were centrifuged at 
! ! !
!
!
37!
1000rpm for 5 min and 10µL of supernatant from V-bottom plate was transferred to a 
flat bottom plate and the remaining supernatant aspirated. Pellets from V-bottom plates 
were treated with 20µL of 0.5% Triton-X in 1X Tyrode’s buffer and transferred to a 96-
well flat bottom plates. A solution of p-Nitrophenyl-N-acetyl-beta-D-glucosaminidine (p-
NAG) substrate (50µL of 4mM) was added to each well in a 96-well plate containing 
supernatant and cell lysate and incubated for 60 min at 37° C. Glycine (0.2M), pH 10.7 
(150µL) was added to each well and the absorbance measured at 405 nm. To calculate 
the percent of mast cell degranulation, the optical densities (O.D.) of samples were 
multiplied twice and average cell supernatant was divided by average cell supernatant 
and average cell lysate and multiplied by 100. 
 
 
 
Figure 5. Equation for the calculation of percent of mast cell degranulation. 
 
 
Figure 6. Illustration of mast cell degranulation assay; treatment, priming and 
challenge. 
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Statistical Analysis 
The number of times experiments were repeated are as indicated in results. 
Experiments were analyzed using Student’s t-test and error bars denote standard errors of 
the mean (SEM). Differences were considered statistically significant if P was < 0.05. (* 
= <0.05; ** = 0.01 ; *** = 0.001; **** = 0.0001). NS = not significant.  
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CHAPTER THREE 
RESULTS 
Characterization of Biofilm Formation by Bacillus subtilis Mutants 
B. subtilis from a WT undomesticated strain forms a robust biofilm and pellicle 
while an ΔepsH mutant does not. The epsA-O operon encodes for enzymes that aid in the 
formation of biofilms and pellicles (Branda et al. 2006). To assess if deletions of 
individual genes in the epsA-O operon affected the ability of B. subtilis to form biofilms 
or pellicles, pellicle and biofilm formation assays for each of the 15 gene strains were 
performed. Deletions of 11 of these genes resulted in the loss of both pellicle and biofilm 
formation. Four strains, ΔepsA, ΔepsB, ΔepsJ, and ΔepsO were still capable of forming a 
full biofilm or pellicle in the absence of the strains’ corresponding deleted gene (Figures 
7A and 8A). The biofilms produced by strains of ΔepsC, ΔepsI, ΔepsK, and ΔepsN B. 
subtilis were capable of forming what look like weak biofilms but unable to form 
pellicles. A complete lack of pellicle and biofilm formation was exhibited in ΔepsD, 
ΔepsE, ΔepsF, ΔepsG, ΔepsH, ΔepsL, and ΔepsM strains (Figures 7A, 8A, and 9). Of 
the strains quantitated for the strength of biofilm produced, only ΔepsJ formed a 
statistically significant biofilm that was comparable to WT B. subtilis (Figure 9).  
Deletion of sinR, a global repressor gene of the epsA-O operon, and tasA, an 
extracellular protein, results in increased EPS production as well as increased release of 
EPS into culture medium (Branda et al. 2006; Chu et al. 2006). Deletion of genes in the 
epsA-O, in addition to sinR and tasA deletions, provides a means to study EPS produced 
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by these mutant strains. These triple mutants, ΔepsA-O, ΔsinR, and ΔtasA, are 
derivatives of B. subtilis DS991 (ΔtasA and ΔsinR). EPS from B. subtilis DS991 was 
previously demonstrated to protect mice from C. rodentium-associated disease. Strains, 
with three deletions to sinR, tasA and epsA-O gene demonstrated a reduced capacity to 
form a biofilm (Figures 7B and 8B). 
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Figure 7. Effect of deletion to genes in the epsA-O operon on biofilm and pellicle 
formation in B. subtilis. Photos of biofilm columns represent phase contrast images of 
colonies grown overnight on LB plates with 1.5% agar, showing effects of mutations in 
the indicated genes on the formation of a biofilm. Photos from pellicle columns depict 
top-down images of microtiter wells (24-well plate) in which cells were grown in LB 
media for 24 hr at 37°C. All strains used are as indicated in Table 4. A. Biofilm and 
pellicle formation of strains of B. subtilis with a single deletion to a gene of the epsA-O 
operon. B. Biofilm and pellicle formation of strains of B. subtilis with a deletion to a gene 
of the epsA-O operon, sinR, and tasA.  
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Figure 8. Effect of deletion in genes of the epsA-O operon on biofilm and pellicle 
formation in B. subtilis. A. Biofilm and pellicle formation of strains of B. subtilis with a 
single deletion to a gene of the epsA-O operon. B. Biofilm and pellicle formation of 
strains of B. subtilis with a deletion to a gene of the epsA-O operon, sinR, and tasA. All 
strains are as indicated in Table 4. Data provided by our collaborator, Dr. Daniel Kearns, 
Indiana University, Bloomington, IN. 
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Figure 9. Effect of deletions of genes of the epsA-O operon on biofilm formation in B. 
subtilis. Bars represent the average absorbance (550 nm) of crystal violet as a 
measurement of biofilm in wells in a 96-well microtiter dish following aspiration, crystal 
violet staining, and addition of ETOH. Bacterial cultures were grown in LB media and 
incubated at 37°C for 24 hr. Strains used are as indicated in Table 4. Biofilms of B. 
subtilis mutants were significant compared to ΔepsH when P<0.05(*) (Student’s t-test). 
Error bars represent the SEM. 
 
 
DNA Sequence Analysis of Genes of the epsA-O Operon and Comparison to 
Homologous Genes  
EPS produced by B. subtilis is thought to be synthesized by the enzymes encoded 
in the epsA-O operon. To identify and compare genes of the epsA-O operon to 
homologous genes, sequences of the epsA-O operon in B. subtilis strain NCBI 3610 were 
obtained from the NCBI website. Amino acid sequences from all epsA-O operon genes 
(epsA, epsB, epsC, epsD, epsE, epsF, epsG, epsH, epsI, epsJ, epsK, epsL, epsM, epsN, 
epsO) were aligned with Escherichia coli and Staphylococcus aureus sequences using the 
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basic local alignment search tool (BLAST) from the NCBI website. Of the 15 genes of 
the epsA-O operon, 6 genes, epsD, epsE, epsF, epsH, epsJ, and epsL, have sequences that 
suggest they code for a glycosyltransferase. Two genes, epsE and epsL seem to have bi-
functional activity. Additionally, the remaining genes of the operon may code for 
modulator of a tyrosine kinase, a tyrosine kinase, a UDP-sugar epimerase, a membrane 
protein, 2 pyruvyl transferases, flippase, an acetyltransferase, and an aminotransferase 
(Table 4) (Data provided by our collaborator, Dr. Daniel Kearns, Indiana University, 
Bloomington, IN). The large number of glycosyltransferases suggest that carbohydrate 
modification may play an important role in EPS production. 
 
Characterization of EPS Produced by Bacillus subtilis Mutants 
To assess the size of EPS synthesized by B. subtilis strains, samples of EPS were 
run on a fast protein liquid chromatography apparatus with standards of multiple sizes to 
provide points of reference. Nine different samples of over-producing and over-secreting 
strains of B. subtilis with single deletions of genes of the epsA-O operon were used 
including all strains with deletions of genes that encode for a putative glycosyltransferase; 
ΔepsD, ΔepsE, ΔepsF, ΔepsH, ΔepsJ, and ΔepsL. Samples were run on a Superose 6 
matrix, a composite of cross-linked agarose gel (GE Lifesciences), and fractions were 
assayed for the presence of carbohydrates by the phenol sulfuric acid assay. All samples 
eluted from the column at similar volumes, suggesting the size/shape of these 
polysaccharides are generally similar to each other. The samples eluted between the IgG 
(150kDa) and fructose standards, suggesting that EPS in all of the mutants is less than 
150 kDa (Figure 10).     
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Differences in the absorbance were found among the different forms of EPS, 
suggesting that some forms of EPS, such as ΔepsM and ΔepsN, secrete more EPS than 
other strains, such as ΔepsG or ΔepsH (Figure 10). We conclude that all B. subtilis 
mutant strains tested make EPS that is similar in size to WT EPS. 
 
 
 
Figure 10. Assessment of the size of EPS isolated from different B. subtilis strains. 
Graph depicts the absorbance of fractions eluted from a size exclusion column with a 
Superose 6 matrix. Samples of EPS from strains of B. subtilis are as indicated in Table 4. 
Blue arrows represent standards of Blue Dextran (>2000kD), apoferritin (480kD), IgG 
(150kD), and fructose which were used as reference points.   
 
 
EPS from WT B. subtilis is composed of different monosaccharide constituents, 
mannose (88%) and glucose (12%) (Jones et al. 2014). To assess if there were differences 
in the carbohydrate composition of EPS isolated from different B. subtilis strains WT 
EPS, and EPS from ΔepsH and ΔepsF strains were analyzed using an enzymatic test. WT 
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EPS protects from disease caused by C. rodentium and EPS from ΔepsH does not. If 
there are differences in the composition of EPS from protective and non-protective B. 
subtilis strains, then it might help identify the type of monosaccharide important for 
protection. 
The enzymatic test measures the change in absorbance that is a result of NADPH 
production from enzyme and monosaccharide interactions. Monosaccharides were 
hydrolyzed and phosphorylated by Hexokinase (HK). Glucose-6-phosphate 
dehydrogenase (G6PDH), which identifies glucose-6-phosphate as its substrate, and 
phosphomannose isomerase (PMI), which identifies mannose-6-phosphate as its substrate, 
were used to measure the levels of glucose and mannose in EPS from WT B. subtilis as 
well as EPS from ΔepsH and ΔepsF. There were no discernable differences in glucose or 
mannose content between the three EPS samples used (Table 1, A-C). These data 
confirm our current knowledge of WT EPS and suggest that the composition of EPS from 
two B. subtilis mutants is similar; however, this assay may not have a sufficiently high 
level of sensitivity to identify differences. 
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0 min 20 min 10 min 30 min 
 A. Hexokinase Glucose Fructose Mannose 
          
WT EPS 0.000 0.264 0.100 0.518 
Sucrose 0.000 0.511 0.156 0.062 
Mannose 0.000 0.041 0.002 0.835 
 B. Hexokinase Glucose Fructose Mannose 
          
WT EPS 0.000 0.243 0.021 0.155 
ΔepsH 0.000 0.158 0.005 0.250 
Sucrose 0.000 0.391 -0.004 0.022 
Mannose 0.000 -0.019 0.001 0.340 
 C. Hexokinase Glucose Fructose Mannose 
          
WT EPS 1:8 0.000 0.081 0.009 0.087 
WT EPS 1:4 0.000 0.135 0.004 0.139 
WT EPS 1:2 0.000 0.235 0.014 0.355 
ΔepsF 1:2 0.000 0.268 0.001 0.479 
Sucrose 0.000 0.694 0.092 0.043 
Mannose 0.000 0.024 0.011 0.782 
Table 1. Determination of monosaccharide composition of EPS from B. subtilis 
strains. Table values represent the absorbance of samples of EPS from strains of B. 
subtilis. Strains of B. subtilis are as indicated in Table 4. Columns indicate the enzyme 
used in reaction as well as time of reaction prior to measurement. Sucrose and Mannose 
were used as positive and negative controls respectively. A. Absorbance of WT EPS B. 
Absorbance of WT EPS and EPS from ΔepsH C. Absorbance of WT EPS and EPS from 
ΔepsF. Samples were diluted as indicated (1:2, 1:4, and 1:8).!
 
EPS from WT B. subtilis characterized by gas chromatography and mass 
spectroscopy suggests that WT EPS has multiple glycosyl linkage residues. Major 
glycosyl linkage residues include a 2,6 linked Mannopyranosyl residue (2,6-Man) (31.8% 
of total EPS), terminal mannopyranosoyl residue (t-Man) (29.9% of total EPS), and a 3 
linked mannopyranosyl residue (2-Man) (15% of total EPS) (Jones et al. 2014). To assess 
the composition of polysaccharide samples, with a more sensitive assay, and to identify 
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linkages in EPS from B. subtilis strains, gas chromatography, mass spectrometry, and 
NMR spectroscopy were performed on samples of EPS by our collaborator, Dr. Neil 
Price, USDA. EPS from WT B. subtilis, as well as EPS from ΔepsE, ΔepsJ, and ΔepsM 
strains were used. If there are large differences in the composition and linkages of EPS 
from non-protective mutant strains of B. subtilis, such as ΔepsM, when compared to WT 
B. subtilis or protective strains, such as ΔepsJ and ΔepsE, then the differences in 
monosaccharide composition and linkages may identify important residues for protection. 
 
Sample Mannose (%) Glucose (%) 
WT B. subtilis 73.87 26.13 
ΔepsE 76.27 23.73 
ΔepsJ 88.31 11.69 
ΔepsM 82.14 17.86 
Table 2. Percent composition of glucose and mannose from B. subtilis strains. 
Compositional analysis by gas chromatography and mass chromatography. EPS from 
strains are as indicated in Table 4. Data provided in collaboration with Dr. Neil P.J. 
Price, NCAUR-ARS-USDA, Peoria, IL. 
 
 
 
Figure 11. Primary repeating structure and linkage of EPS-J. Structure and linkage 
of EPS from B. subtilis ΔepsJ. Structure was determined from data gathered by 
permethylation linkage and NMR spectroscopy. Data provided in collaboration with Dr. 
Neil P.J. Price, NCAUR-ARS-USDA, Peoria, IL 
 
 
 
Samples of WT EPS had mannose and glucose levels consistent with previous 
studies (Jones et al. 2014). Samples of EPS from B. subtilis mutants had levels of 
mannose and glucose that were similar to WT EPS (Table 2). Additionally, preliminary 
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NMR experiments and analysis on EPS from ΔepsJ suggests similar composition and 
linkage that has been reported from WT EPS (Data not shown). These data confirm our 
current knowledge of the composition of WT EPS and suggest that the composition of 
EPS from B. subtilis mutants may be similar in monosaccharide composition, and in the 
case of EPS from ΔepsJ, similar linkage (Figure 11).  
 
Recognition of EPS Isolated from Bacillus subtilis Mutants by Anti-EPS Serum 
 WT EPS is recognized by polyclonal rabbit anti-EPS serum. To assess if EPS 
from B. subtilis mutants produce EPS similar to WT EPS, a modified western blot was 
performed. If EPS from B. subtilis strains is similar to WT EPS, then polyclonal rabbit 
anti-EPS serum should also recognize EPS from other B. subtilis strains. All mutant 
forms of EPS were recognized by polyclonal rabbit anti-EPS serum. This suggests that 
EPS from B. subtilis mutants is relatively similar to WT EPS. Additionally, EPS samples 
did not migrate into the stacking gel or resolving gel and are primarily at the interface 
between buffer and stacking gel (5%) or interface between stacking gel and resolving gel 
(8%). This suggests that EPS samples were too large or did not have a sufficient negative 
charge to migrate into the gel (Figure 12). 
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Figure 12. Modified western SDS-PAGE performed on EPS from B. subtilis strains. 
Strains used are as indicated in Table 4. Blue line represents buffer/stacking gel interface. 
Red line indicates stacking gel/resolving gel interface. Green line represents flagellar 
protein complex. 
 
Recognition of EPS by Peritoneal Cells 
 WT EPS binds to peritoneal cells and exerts an immunomodulatory effect (Jones 
et al. 2014). EPS from a ΔepsH mutant binds to peritoneal cells less well than WT EPS. 
Results from the characterization of EPS from B. subtilis strains suggest that EPS is made 
by these strains and that it is similar in composition to WT EPS. To determine if EPS 
from other B. subtilis strains binds to peritoneal cells, we performed flow cytometry and 
assessed the binding of EPS to cells that had been incubated with EPS and rabbit anti-
EPS serum. Data suggest that EPS from B. subtilis strains binds the surface of peritoneal 
cells at varying levels. EPS from ΔepsD, ΔepsE, ΔepsF, ΔepsG, ΔepsH, and ΔepsL bind 
peritoneal cells similar to WT EPS (Figure 13). More EPS binding from ΔepsJ, ΔepsM, 
and ΔepsN is found that with WT EPS. These data suggest that EPS binding to peritoneal 
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cells is not dependent on the ability of the B. subtilis strain to form a biofilm as EPS 
from ΔepsJ, a strain that does form a biofilm, and EPS from ΔepsM and ΔepsN, strains 
that do not form biofilms, bind peritoneal cells (Figure 7A, Figure 8A, Figure 13). 
EPS from ΔepsH was not previously believed to bind to peritoneal cells. 
Additionally, EPS from B. subtilis strains used in this experiment was not column 
purified. Taken together, these data suggest that pre-column purified EPS from a number 
of B. subtilis mutants can bind to peritoneal cells. Alternatively, there may be something 
in the pre-column sample that also binds peritoneal cells and is recognized by the rabbit 
anti-EPS serum. 
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Figure 13. Binding of EPS from B. subtilis strains to peritoneal cells. Flow cytometric 
analysis of EPS binding to the surface of peritoneal cells from naïve C57Bl/6 mice. 
Granulocytes were selected on forward and side scatter. The x-axis represents fluorescent 
intensity of rabbit anti-EPS serum. The y-axis represents normalized cell count. EPS from 
strains are as indicated in Table 4. FITC-conjugated goat anti-rabbit Ig was used to detect 
rabbit anti-EPS Ab. 
  
Genes in the epsA-O Operon are Required for Protection from the Enteric 
Pathogen, Citrobacter rodentium 
Mice treated with WT B. subtilis spores by oral gavage or WT EPS by 
intraperitoneal injection and then infected with C. rodentium do not display characteristic 
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symptoms of disease. Mice treated with spores or EPS from a ΔepsH mutant and then 
infected with C. rodentium are not protected from C. rodentium-associated disease (Jones 
and Knight 2012). To determine which genes encoded in the epsA-O operon are needed 
to confer protection against C. rodentium, B. subtilis spores with a single gene from the 
epsA-O operon deleted were given to mice by oral gavage and mice were infected with C. 
rodentium. If certain genes in the epsA-O operon are required to produce a protective 
form of EPS, then mice treated with B. subtilis with deletions of the genes of the epsA-O 
operon will not be protected from C. rodentium-associated disease. 
All mice treated with B. subtilis had detectable levels of B. subtilis in their stool 
five days post treatment. Additionally, all mice treated with C. rodentium had detectable 
levels of the pathogen on day 10 of the experiment (Figure 15, A-B). These data suggest 
that any symptoms of disease exhibited by mice were not due to lack of B. subtilis 
persistence nor to a lack of colonization by the infectious pathogen, C. rodentium. 
Furthermore, colonization with B. subtilis mutants did not seem to correlate with 
protection, as spores of ΔepsJ and ΔepsK mutants were found at relatively high spore 
concentrations in mice; however, disease markers suggest that ΔepsJ is protective while 
ΔepsK is not (Figure 15A and Figures 16-17, A-D). Conversely, colonization with C. 
rodentium did not correlate with disease severity, as mice treated with ΔepsA and ΔepsB 
spores were colonized with a two fold difference of C. rodentium (Figure 15B), but 
showed disease markers that were relatively the same (Figures 16-17, A-D, Figure 18). 
Mice treated with WT B. subtilis spores do not develop loose and unformed 
stools, while mice treated with ΔepsH spores do. Of the 15 mutant strains of B. subtilis 
tested, 13 did not protect mice from developing diarrhea. Mice treated with B. subtilis 
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spores of ΔepsE and ΔepsJ did not develop diarrhea (Figure 17C). In addition to 
diarrhea, mice with C. rodentium-associated disease have enlarged spleens relative to 
body weight. To assess if B. subtilis strains could protect from splenic inflammation, the 
spleens of mice were harvested at day 10 or 11 post infection with C. rodentium. Of the 
mice treated with B. subtilis mutants, 6 of 15 treatment groups did not have enlarged 
spleens. Mice treated with B. subtilis mutants ΔepsE and ΔepsJ had spleen to body 
weight ratios similar to PBS control (Figure 17D). 
The large intestines from mice infected with C. rodentium exhibit changes to the 
colonic architecture. These changes include elongation of crypts of the large intestines, 
crypt hyperplasia, (Mundy et al. 2005) and loss of goblet cells (Jones and Knight 2012). 
Mice treated with WT B. subtilis spores do not have elongated crypts or lower levels of 
goblet cells. Uninfected mice have a crypt height of approximately 200µm. Of the 15 B. 
subtilis mutant strains tested, two, ΔepsE and ΔepsJ did not have signs of elongated 
crypts or loss of goblet cells. Mice treated with ΔepsL spores had the largest crypt height; 
and therefore, the most inflamed colons of all groups. Mice treated with spores of ΔepsE 
and ΔepsJ also had no change to goblet cells over untreated mice (Figure 16, A-B). 
From these data, we conclude that only two B. subtilis mutants, ΔepsE and ΔepsJ, 
conferred complete protection, suggesting that most genes in the epsA-O operon are 
necessary to produce a protective form of EPS. 
Interestingly, mice treated with EPS from WT B. subtilis and infected with C. 
rodentium have lower levels of the inflammatory chemokine KC. To assess for protection 
against C. rodentium by B. subtilis spores, an ELISA to assay the level of KC in sera was 
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performed. Data suggest that there is no correlation between protection and KC 
cytokine in mice treated with B. subtilis spores (Figure 14 and Figures 16-17, A-D).  
 
 
 
 
Figure 14. Levels of serum KC, an inflammatory chemokine, in mice treated with B. 
subtilis spores and infected with C. rodentium. Assessment of B. subtilis spores on C. 
rodentium-associated disease 10 days post-infection (dpi) of WT mice. B. subtilis strains 
are as indicated in Table 4. Results are averages from at least 3 mice. Error bars represent 
the SEM. 
 
 
 
 
 
 
 
! ! !
!
!
56!
 
Figure 15. Colonization of B. subtilis mutants and C. rodentium. Results are averages 
from two independent experiments; a total of 6 mice were assessed. Error bars represent 
the SEM. A. Persistence of spores of B. subtilis epsA-O mutants in the colon of mice for a 
period of five days post oral gavage. B. Colonization of C. rodentium in feces of mice at 
day 10 or 11.  
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Figure 16. Effect of B. subtilis mutants on C. rodentium-associated disease 10 days 
post-infection. Infection-induced alterations in colon which were quantified by 
measuring crypt heights and goblet cells per crypt height. Results are averages from two 
independent experiments; a total of 6 mice were assessed for each group. Error bars 
represent the SEM. A. Distal sections of fixed colons were measured for crypt height. 
Columns at or below red bar suggest no C. rodentium-associated disease. B. Number of 
goblet cells per crypt height. Columns at or above red bar suggest no C. rodentium-
associated disease. Treatments with B. subtilis spores and infection with C. rodentium 
were compared to naïve mice. Treatments were significant compared to naïve untreated 
mice when P< 0.05. Data were analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** = 
0.001; **** = 0.0001; NS = not significant. 
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Figure 17. Effect of B. subtilis mutants on C. rodentium-associated disease 10 days 
post-infection. Infection-induced symptoms of C. rodentium-associated disease. C. 
Diarrhea score D. Spleen to weight ratio. Results are averages from two independent 
experiments; a total of 6 mice were assessed for each group. Error bars represent SEM. 
Treatments with B. subtilis spores and infection with C. rodentium were compared to 
naïve mice. Columns at or below red bar suggest no C. rodentium-associated disease 
Treatments were significant compared to naïve untreated mice when P< 0.05. Data were 
analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** = 0.001; **** = 0.0001; NS = not 
significant. 
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Figure 18. Representative photos of H&E stained longitudinal colonic sections from 
mice treated with B. subtilis and infected with C. rodentium. Samples include 
untreated mice (Naïve-PBS), B. subtilis and infected with C. rodentium (3610 + Cr), B. 
subtilis mutants ΔepsE and ΔepsJ and infected with C. rodentium, and mice infected only 
with C. rodentium. Black bars on the lower right hand corner indicate a measurement of 
200µm. Data shown are representative of results from three independent experiments. 
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Protection from C. rodentium-Associated Disease by Bacillus subtilis var. natto 
Natto is a traditional fermented soybean dish eaten in a number of Asian 
countries. Traditional Natto is fermented in the presence of B. subtilis var. natto and 
these strains may confer protection against C. rodentium-associated disease. 
Bacterial isolates from all three brands of Natto had similar colony morphology 
with some being hazier than others and did not have the characteristic colony wrinkling 
present in B. subtilis NCBI 3610 (Data not shown). By MALDI-TOF MS analysis, all 
bacterial isolates were identified as B. subtilis (Table 2). 
All mice treated with B. subtilis var. natto spores had detectable levels of B. 
subtilis following treatment that were comparable to WT B. subtilis spores. Additionally, 
all mice infected with C. rodentium were colonized with the pathogen at day 10 or 11. 
These data suggest that mice were colonized by B. subtilis and C. rodentium (Figure 
19B). 
To assess protection from C. rodentium-associated disease, we measured the crypt 
heights of mice treated with Natto spores and infected with C. rodentium. Mice receiving 
spores from any of the 3 Natto isolates had on average, shorter crypt heights, more goblet 
cells per crypt, and significantly better stool scores than mice infected with C. rodentium 
alone. These data suggest that mice treated with B. subtilis from Natto were protected 
from diarrhea and infection-induced alterations to the colon (Figure 20-21, A-C). 
Additionally, the spleen to weight ratios of mice treated with Natto 1, Natto 2, and Natto 
3 were similar to PBS controls and WT B. subtilis suggesting that mice treated with 
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spores from Natto had significantly less systemic inflammation than mice treated with 
C. rodentium alone (Figure 21D). 
Although mice treated with Natto 3 spores had significantly reduced crypt 
heights, their stool scores, reduced spleen to body weight ratio, and goblet cells per crypt 
(Figure 19:1-2, A-D, Figure 21) suggest that mice treated with spores from Natto 3 were 
protected. Collectively, these data suggest that a commercially available product can 
protect against enteropathogenic disease; and more importantly, that some brands confer 
more protection than others. 
 
 
Table 3. MALDI-TOF MS analysis of bacteria isolated from Natto. All isolates with 
different colony morphologies were selected for analysis. Analyte ID indicates product, 
best match and second best match indicate the primary and secondary species. A Score 
value >2 is significant to the species level (Bruker MALDI-TOF MS Research Database). 
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Figure 19. Colonization of B. subtilis var. natto and C. rodentium. Results are averages 
from two independent experiments; a total of 6 mice were assessed. Error bars represent 
the SEM. A. Persistence of B. subtilis var. natto spores in the colon of mice for a period 
of five days post oral gavage. B. Colonization of C. rodentium in feces of mice 10 or 11 
dpi.  
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Figure 20.!Effect of B. subtilis var. natto on C. rodentium-associated disease 10 days 
post-infection. Infection-induced alterations in colon were assessed by measuring crypt 
heights and goblet cells per crypt height. Results are averages from two independent 
experiments; a total of 6 mice were assessed for each group. Error bars represent the 
SEM. A. Distal sections of fixed colons were measured for crypt height. Bars at or below 
red bar suggest no C. rodentium-associated disease. B. Number of goblet cells per crypt 
height. Columns at or above red bar suggest no C. rodentium-associated disease. 
Treatments with B. subtilis spores and infection with C. rodentium were compared to 
naïve mice. Treatments were significant compared to naïve untreated mice when P<0.05. 
Data were analyzed by Student’s t-test, * = <0.05; ** = 0.01; *** = 0.001; **** = 
0.0001; NS = not significant. 
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Figure 21.!Effect of B. subtilis var. natto on C. rodentium-associated disease 10 days 
post-infection. Infection-induced symptoms of C. rodentium-associated disease. C. 
Diarrhea score and D. Spleen to weight ratio. Bars above the red line indicate no 
protection. Columns at or below red bar suggest no C. rodentium-associated disease. 
Results are averages from two independent experiments; a total of 6 mice were assessed 
for each group. Error bars represent SEM. Treatments with B. subtilis spores and 
infection with C. rodentium were compared to naïve mice. Treatments were significant 
compared to naïve untreated mice when P<0.05. Data were analyzed by Student’s t-test, * 
= <0.05; ** = 0.01; *** = 0.001; **** = 0.0001; NS = not significant.  
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Figure 22. Representative photos of H&E stained longitudinal colonic sections from 
mice treated with B. subtilis and infected with C. rodentium. Photos are representative 
of colon sections from untreated mice (Naïve-PBS), treated with B. subtilis spores and 
infected with C. rodentium (3610 + Cr), treated with B. subtilis var. natto spores and 
infected with C. rodentium (Natto 1 + Cr, Natto 2 + Cr, or Natto 3 + Cr), and mice 
infected only with C. rodentium. Black bars on the lower right hand corner indicate a 
measurement of 200µm. Data shown are representative of results from three independent 
experiments. 
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Characterization of Immunomodulatory Effects of Protective EPS isolated from 
B. subtilis mutants 
 Mice treated with WT B. subtilis spores or WT EPS and sensitized to OVA do not 
develop OVA specific Abs (Swartzendruber and Knight, unpublished data). If strains of 
B. subtilis are protective in a C. rodentium model of disease, then these same strains may 
also display immunomodulation in other models. We tested if B. subtilis mutant strains 
that are either protective or not protective in the C. rodentium disease model behave 
similarly in the OVA sensitization model. WT and mutant B. subtilis spores from strains 
ΔepsH, ΔepsF, and ΔepsJ were orally administered to mice 3 days prior to intraperitoneal 
injection of OVA and after 14 days, we used ELISA to determine the level of serum IgG1 
anti-OVA. We found that mice treated with spores from ΔepsJ strain had low levels of 
IgG1 anti-OVA Ab, similar to that from mice treated with WT B. subtilis spores.  In 
contrast, mice treated with spores from ΔepsH and ΔepsF, strains that do not confer 
protection against C. rodentium, did not decrease the level of IgG1 anti-OVA, compared 
to mice that received no B. subtilis.  Mice treated with ΔepsH had low OVA-specific 
IgG1 and mice treated with ΔepsF had higher levels of OVA-specific IgG1. These data 
suggest that a strain of B. subtilis protective against C. rodentium, ΔepsJ, is 
immunomodulatory in a sensitization model. Interestingly, a strain of B. subtilis that did 
not confer protection against C. rodentium, ΔepsH, seems to have some 
immunomodulatory effect as there was a reduced level of OVA-specific Abs in serum 
from these mice (Figure 23). Taken together, this preliminary experiment demonstrates 
that strains of B. subtilis not protective in a C. rodentium model may still exert an 
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immunomodulatory effect on the host, and that ΔepsJ, a strain protective in a C. 
rodentium model, is also immunomodulatory in other models of study. 
 
 
Figure 23. Serum levels of allergen specific IgG1 in sensitized mice. Absorbance of 
OVA specific IgG1 serum levels of mice sensitized with spore preparations from WT B. 
subtilis, ΔepsH, ΔepsF, and ΔepsJ. Error bars represent SEM. 
 
 
 Bacterial polysaccharides can modulate allergic responses (Meier, Bein, Jaques 
1957) and mast cell cultures treated with WT EPS do not degranulate in an in vitro assay. 
To investigate if strains of B. subtilis with immunomodulatory effects modify 
degranulation in mast cells, BMDMCs or PDMCs (Figure 24) were treated with purified 
EPS from ΔepsF and ΔepsJ. Interestingly, compared to naïve BMDMCs, BMDMCs 
treated with EPS-J have a different morphology and do not degranulate (Figure 25, A-B). 
The perimeter around EPS-J treated mast cells have what look to be small circular 
morphologies while naïve mast cells have a characteristic granule appearance. This may 
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suggest that mast cells treated with immunomodulatory EPS causes gradual movement 
of mast cell granules to the perimeter of the cell. 
Data from degranulation assays also suggest that there is a difference between 
mast cells cultured from the bone marrow and mast cells cultured from the peritoneal 
cavity. These preliminary experiments suggest that PDMCs seem to degranulate while 
BMDMCs do not seem to degranulate. Additionally, both PDMCs and BMDMCs have 
high absorbance following challenge and degranulation over naïve mast cells. This may 
suggest that the granules themselves are different in composition as there is less 
absorbance regardless if mast cells degranulated or not (Figures 26-27). Collectively, 
these data suggest that EPS-J has immunomodulatory activity and that it somehow 
modulates the morphology of mast cells and potentially their contents. 
 
 
 
Figure 24. Purity of cultured PDMC and BMDMC isolated from the peritoneum. 
Cells were stained with mast cell markers (CD117 and FcεRI). FACS plots represent 
mast cell purity from peritoneal (PDMC) and bone marrow (BMDMC) isolated from the 
peritoneal cavity of naïve C57Bl/6 mice. 
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Figure 25. Representative photos of mast cells before and after treatment with EPS-
J. Photos represent difference in morphology of naïve BMDMC (A.) and BMDMC 
treated with EPS from ΔepsJ. BMDMCs in culture were cytospun on glass slides and 
stained using Diff-Quick reagents. Images represent magnification at 100x. Red arrows 
indicate circular objects found along the perimeter of mast cells. 
 
 
 
 
Figure 26. Percent degranulation in a mast cell degranulation assay. Percent 
degranulation (A.) and absorbance of lysate from degranulated PDMCs (B.). PDMCs 
were cultured for 10 days, half were treated with purified EPS from B. subtilis ΔepsJ. 
Cells were then treated with IgE anti-DNP and challenged with DNP. 
 
A.$ B.$
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Figure 27. Percent degranulation in a mast cell degranulation assay. Percent 
degranulation (C.) and absorbance of lysate from degranulated BMDMCs (D.). 
BMDMCs were cultured for 10 days, half were treated with purified EPS from B. subtilis 
ΔepsJ. Cells were then treated with IgE anti-DNP and challenged with DNP. 
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Table 4. Characterization of B. subtilis mutants. Strain column indicates strain of B. 
subtilis used. Mutation column indicates which genes are deleted in the strain. Proposed 
function indicates the function of the deleted gene determined through BLAST. 
Phenotype is determined by the morphology of B. subtilis. Biofilm is indicated by the 
growth of bacteria and degree of opacity; ++ (strong biofilm), + (weak biofilm), and ---- 
(no biofilm). Pellicle formation is indicated by formation of a biofilm at the air liquid 
interface; ++ (strong pellicle), + (weak pellicle), and ----- (no pellicle). ETOH: Sup 
precipitate are indicated as + (precipitate) or ---- (no precipitate) when a visible 
precipitate formed after addition of EtOH (50% final) to supernatant from an overnight 
culture of B. subtilis. Protection from disease is indicated as + (protection) or ---- (no 
protection) when mice are protected by three of four symptoms of disease (diarrhea, 
goblet cell loss, crypt hyperplasia, and spleen to weight ratio). WT = Wild Type; ND = 
Not Determined; WM = Wrinkled Morphology; WFM = Wrinkled and Flat Morphology. 
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CHAPTER FOUR 
DISCUSSION 
A Unique and Novel Approach to Studying Polysaccharide Biosynthesis 
Carbohydrate polymers, specifically bacterial polysaccharides, have a wide 
variety of uses in public, private, and academic settings. Presently, their compositions, 
biosynthesis, and mechanisms of immunomodulation are poorly understood. This study 
used a unique and novel approach to better understand the synthesis of a complex 
polysaccharide and its immunomodulatory activity. Using numerous approaches, 
investigators have tried to characterize the enzymes that are involved in the biosynthesis 
of bacterial polysaccharides (Freitas, Alves, Reis 2011; Öner 2013; Rehm 2010; Roux et 
al. 2015; Schmid, Sieber, Rehm 2015; Wang et al. 2000). To our knowledge, our study, 
which focuses on changes to a complex polysaccharide and not the enzymes or genes 
involved in its biosynthesis, is one of the first to investigate what changes occur to a 
polysaccharide during its biosynthesis. 
 
Summary of Findings 
EPS from WT B. subtilis contributes to the formation of a robust biofilm and 
pellicle, and protects against all disease markers of the murine enteropathogen C. 
rodentium. A single deletion of the epsH gene of the epsA-O operon inhibits the ability of 
B. subtilis to form a strong biofilm and protect mice from C. rodentium-associated 
disease. Mutants of B. subtilis 
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with deletions of the genes encoded in the epsA-O operon were assessed for their 
ability to form a biofilm or pellicle, and their ability to protect against C. rodentium-
associated disease. EPS purified from B. subtilis strains were characterized for their 
physical and chemical properties. 
The results from the biofilm and pellicle formation assays confirm that EPS is a 
key component that contributes to the formation of a biofilm. Experiments that assess the 
biofilm and pellicle formation of B. subtilis strains provide limited information on the 
characteristics of EPS produced by these mutants. There is no correlation with the 
formation of a biofilm following deletion of the genes in the epsA-O operon and 
protection from C. rodentium. Spores of ΔepsE, a non-biofilm forming strain, or spores 
of ΔepsJ, a biofilm forming strain, were both protective against C. rodentium-associated 
disease. Therefore, the ability to form a biofilm is independent of protection. 
Our results indicate that there is no single gene in the epsA-O operon responsible 
for protection from the enteropathogen C. rodentium. Additionally, lack of protection 
from C. rodentium is not due to the lack of a polysaccharide being produced. To our 
knowledge, all B. subtilis mutants produce some form of polysaccharide. From 
preliminary experiments, it also seems that the monosaccharide composition from ΔepsE, 
ΔepsF, ΔepsH, ΔepsJ, and ΔepsM does not correlate with protection. Interestingly, EPS 
from B. subtilis with a deletion to epsF, a glycosyltransferase, elutes from a size 
exclusion column similar to EPS from WT B. subtilis. This is contrasted with EPS from a 
ΔepsH mutant that elutes after WT EPS suggesting it is smaller in size. The use of EPS 
from an epsF mutant may serve as a better negative control then EPS from an epsH 
mutant as it elutes out more closely with WT EPS preparations. 
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A closer analysis of the composition of EPS suggested that there was a high 
degree of similarity in the mannose and glucose concentrations in mutant forms of EPS. 
Conformational studies were completed using NMR spectroscopy and suggest that, from 
the samples tested, (ΔepsE, ΔepsJ, and ΔepsM) the majority of EPS is made of mannose 
and a minority is made of glucose. There does not seem to be a correlation with mannose 
or glucose concentration and protection or immunomodulatory activity. Therefore, 
protection by EPS is not due to the type or amount of monosaccharide found in EPS. The 
glycosidic bonds present in protective forms of EPS, such as the α1,6-Man or α1,2-Man 
that are present in EPS from ΔepsJ, may be key linkages for immune modulation. Studies 
on the bonding profiles in EPS from ΔepsE, which is protective, and ΔepsF, which is not 
protective, are already underway.  
From preliminary NMR analyses of EPS from ΔepsJ, the data suggest that a long 
polymer is present. Loss of any the enzymes encoded by the epsA-O operon may result in 
altered EPS structure. These modifications could eliminate or mask residues important 
for interaction with the immune system. These deletions could also eliminate or 
drastically reduce EPS production or limit the stability of the polysaccharide such that it 
degrades faster than normal. Until better understandings of either enzyme activity, or 
differences between individual forms of EPS are elucidated, the protective residues will 
remain a mystery. 
Peritoneal cells collected from B57Bl/6 mice intraperitoneally injected with WT 
EPS are believed to become anti-inflammatory alternatively-activated M2-Mϕ. Mice 
treated with WT EPS developed higher levels of M2-Mϕ than mice treated with EPS 
from ΔepsH. When peritoneal macrophages from mice treated with WT EPS are co-
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cultured with naive CD4+ T cells, in vitro T-cell proliferation is suppressed (Paynich 
and Knight, unpublished data). Preliminary experiments using EPS from ΔepsJ, which is 
protective against C. rodentium, and ΔepsF, which is not protective against C. rodentium, 
suggest that ΔepsJ does skew cells of the peritoneal cavity to become M2-Mϕ and these 
cells can suppress T cell proliferation while cells treated with ΔepsF cannot (Data not 
shown). This experiment should also be repeated with EPS from ΔepsE. If EPS from 
ΔepsE is protective against C. rodentium-associated disease, then it should also exert 
immunomodulatory activities similar to WT EPS and EPS from ΔepsJ. 
It is believed that glycosyltransferases, of which the epsA-O operon has six 
putative genes (ΔepsD, ΔepsE, ΔepsF, ΔepsH, ΔepsJ, ΔepsL), are involved in the 
synthesis of EPS. If glycosyltransferases are involved in the synthesis of EPS, then 
deletion of these genes should result in loss of immunomodulatory activity. Surprisingly, 
deletions of two putative glycosyltransferases, epsE and epsJ, did not affect protection. 
Future studies may benefit from investigating the remaining 4 glycosyltransferases to 
identify their activities and substrates. In terms of protection against C. rodentium-
associated disease, it does seem that the remaining 13 genes of the epsA-O operon are 
required for protection. Of these 13 remaining gene products, 4 encode for 
glycosyltransferases.  
The lack of protection conferred by 13 of 15 B. subtilis mutants suggests that 
multiple genes of the epsA-O operon are necessary to produce a protective form of EPS. 
Enzymes produced by genes encoded in the epsA-O operon most likely act sequentially 
to generate functional EPS. It is known that some enzymes, such as EpsB are dependent 
on the activity of EpsA. Additionally, there may be additional bi-functional enzymes, 
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such as EpsE, and the loss of multiple functions contributes to changes of EPS 
produced (Guttenplan, Blair, Kearns 2010). Furthermore, gene products may directly 
interact with each other, may produce necessary substrates for downstream enzymes, or 
modify EPS in such a way that it is not recognized by other enzymes responsible for the 
next stage of EPS synthesis. Elucidation of the order in which proteins act on the 
formation of EPS would clarify the biosynthetic pathway of EPS, identify functionally 
redundant enzymes, and contribute to our understanding of the biofilm matrix of B. 
subtilis. 
While some mutants do not confer protection in a C. rodentium-disease model, 
such as ΔepsH spores, they may have immunomodulatory activity. In a model assessing 
sensitization and development of IgG1, WT EPS or B. subtilis spores inhibited the 
development of IgG1. As a negative control, mice were treated with spores from two 
mutant groups that do not protect against C. rodentium-associated disease, ΔepsH and 
ΔepsF. Treatment of mice with B. subtilis ΔepsH spores prevents these mice from 
developing IgG1 antibodies and is similar to the suppression of IgG1 antibodies observed 
with treatment of WT B. subtilis and ΔepsJ. Conversely, mice treated with ΔepsF, which 
is not protective against C. rodentium, is also unable to suppress IgG1. Collectively, these 
data suggest that there is a very specific component or structure of EPS that is interacting 
with the host and perhaps, the component or structure of EPS needed for 
immunomodulatory activity changes with the models and approaches employed to study 
EPS. There may be multiple residues with immunomodulatory activity. Unique structures 
of EPS that can suppress C. rodentium-associated disease may be different than those that 
suppress the development of IgG1 antibodies.  
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When EPS from strains of B. subtilis were tested for reactivity against rabbit 
anti-EPS antibody, which was generated by immunization with WT EPS, all mutant 
forms of EPS bound this Ab. This finding suggests that the polyclonal antibodies present 
in rabbit anti-EPS serum recognize a similar form of residue on the multiple EPSs from 
B. subtilis strains. This idea is corroborated with the NMR analysis of purified EPS from 
ΔepsE, ΔepsJ, and ΔepsM mutants showing that the structures are very similar to each 
other and to WT EPS. Additionally, there is a high degree of similarity in the sugar 
linkages of at least one strain, ΔepsJ to WT EPS. Further analysis should focus on the 
structural differences of protective forms of EPS compared to non-protective forms of 
EPS. 
 
Confirmation of Protective Strains and Future Models 
The initial studies of protection mediated by EPS were in a C. rodentium model of 
disease. Since these initial experiments, EPS has been shown to confer protection in an 
anaphylaxis model of disease (Swartzendruber and Knight, unpublished data) and a 
model of experimental autoimmune encephalitis (Osborne and Knight, unpublished data). 
Other models of disease may prove useful in exploring the potential uses of EPS as a 
therapeutic. Spores of B. subtilis from ΔepsE, ΔepsH, and ΔepsJ have some form of 
immunomodulatory activity, and they may be beneficial for future studies. Additionally, 
as previously mentioned, spores or purified EPS from ΔepsF may serve as a better 
negative control than ΔepsH, which has demonstrated immunomodulatory activity in a 
model of antigen sensitization. 
In our model of infection with C. rodentium, treatment of mice with B. subtilis 
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spores from WT, ΔepsE, and ΔepsJ mutants protected against disease. This model 
mimics EPEC in humans and would be easy to modify in order to test an EHEC model of 
disease using C. rodentium that expresses shiga toxin. Treatment of mice with these 
spores and then infection with C. rodentium that expresses the stx phage, which carries 
the genes encoding Shiga toxin, would provide further evidence for the protective ability 
of EPS. Additionally, protection via EPS in this model would be of particular interest 
because it would demonstrate that immunomodulation mitigates the damaging and 
debilitating effects of Shiga toxin associated with EHEC. EHEC is a prevalent disease in 
the United States (Crim et al. 2014) and identification of a new therapeutic would be of 
value.  
Finally, experiments have demonstrated that treatment of BMDMCs with WT 
EPS prevents mast cells from degranulating when primed with IgE and challenged with 
corresponding antigen (Swartzendruber and Knight, unpublished data). Preliminary 
experiments suggest that mast cells treated with EPS from ΔepsJ also do not degranulate 
mast cells. Additionally, mast cells treated with EPS from ΔepsJ look characteristically 
different than untreated mast cells. BMDMCs treated with EPS from ΔepsJ appear 
“glassy” with what appears to be granules outside the cell on/near the periphery. It is 
possible that EPS causes slow release of granules, which would explain why no 
degranulation occurs when sensitized cells are challenged with allergen at a later time 
point. Future experiments that follow the morphological changes of mast cells over time 
may provide support for this hypothesis and provide a timeline for EPS action. 
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Potential Probiotics and Caution of Their Use 
A number of probiotic strains of bacteria are either from heritage collections 
isolated from the environment or mass-produced by industry. Depending on the handling 
of these strains, there is the possibility of some level of variation if they are handled in a 
way that favors certain characteristics/traits. All three strains of B. subtilis var. natto were 
protective against C. rodentium-associated disease; however, there was variation in the 
degree of protection as well as the phenotypic characteristics of these strains when grown 
on petri dishes. Polysaccharides can vary greatly depending on the strain and substrates 
used (Öner 2013). EPS contributes to the taste and texture of Natto and most likely, B. 
subtilis strains are different between the different brands of Natto.  
Selection of desired characteristics of bacteria that affect taste, texture, and smell 
of fermented foods may be beneficial for product development; however, they may 
irreparably harm the immunomodulatory effects of B. subtilis. Furthermore, studies using 
bacteria from industry are hampered by the secrecy these companies maintain over 
production of these ‘probiotic’ strains. 
In previous work, mice that were treated with purified EPS and infected with C. 
rodentium did not have an increase in serum KC inflammatory chemokine. In contrast, 
mice treated with B. subtilis spores and then infected with C. rodentium had elevated 
levels of KC. It was expected that treatment with spores would also inhibit serum KC 
inflammatory chemokine but this was not the case. In fact, mice treated with WT B. 
subtilis had levels of KC inflammatory chemokine similar to infection with C. rodentium 
alone. These data highlight the complicated nature of using a live organism and highlight 
the importance of delivering purified EPS. While probiotics, such as B. subtilis, may 
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protect from pathogens, treatment with a live organism may have unintended 
consequences to the host. 
Probiotics are a benefit to society, however, the lack of understanding regarding 
the mechanisms involved in protection is a problem associated with their use. We live in 
an age where the dissemination of information is quick and easy, regardless of the 
accuracy, and as probiotics are relatively un-regulated, they may harm those seeking 
health and wellness. 
 
Further Study of the Enzymes Encoded in the epsA-O Operon 
This study was not focused on the enzymatic activities of the proteins encoded by 
the epsA-O operon; however, a better understanding of the enzymes encoded by the epsA-
O operon will enhance our understanding of bacterial polysaccharide biosynthesis. 
Alternatively, now that it is known that 13 of 15 genes of the epsA-O operon are 
necessary for protection, future studies may benefit from strains of B. subtilis with 
multiple gene deletions to better pinpoint and characterize EPS biosynthesis.  
Genes of the epsA-O operon may be coupled in their production for EPS as is the 
case in other polysaccharides such as Xanthan. Additionally, other studies have 
demonstrated improved yield by overexpressing genes involved in bacterial 
polysaccharide production (Galván et al. 2013). Application of these methods to EPS 
synthesis may prove useful in the production of EPS. 
Furthermore, GTSs are generally promiscuous in the substrates they utilize. If 
GTSs in the epsA-O operon are promiscuous in substrate usage, this would also modify 
the quality of EPS produced. Alternatively, alterations to the growth medium or 
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substrates available to B. subtilis may produce EPS that is characteristically different 
from B. subtilis grown in LB. 
 
Optimization of Purified EPS and Polysaccharide Biosynthesis 
Throughout this study, spores were used in place of purified EPS. Spores 
germinate into vegetative cells and treatment with live organisms increases the number of 
potential interactions occurring in the host as demonstrated in experiments that assessed 
the level of serum KC inflammatory chemokine. Synthesis of polysaccharides in vitro are 
described in the literature and provide a way to optimize and study the activities of single 
enzymes involved in polysaccharide biosynthesis (Braat et al. 2006; Carignatto et al. 
2011; Faijes and Planas 2007; Kobayashi 2007; Steidler et al. 2000; Woodward et al. 
2010; Zhang et al. 2003). The additional products that B. subtilis produces may hamper 
or counteract the protective effects exerted by EPS in such a way that EPS’s efficacy is 
not as high as when it is delivered as a purified substance. Delivery of purified EPS 
would therefore be an ideal approach for future studies. It would also be advantageous to 
encapsulate EPS so it can bypass the gastric acid, and serve as an alternative therapy for 
immunocompromised patients when administration of live organisms is contraindicated. 
Currently, production of EPS yields 10-15mg/L. Concentrations using genetically 
modified bacterial polysaccharide producing strains can be as high as 188g/L (Ruffing 
and Chen 2006). The are numerous reports on the optimization and increased yield of 
bacterial polysaccharides through various methods. Methods to increase EPS yield 
include: increasing the pool of polysaccharide precursors (mannose and glucose for EPS), 
over-expression of gene(s) involved in synthesis, insertion of multiple plasmids encoding 
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enzymes needed for polysaccharide production, higher ethanol (v/v) during 
precipitation, precipitation with the low molarity salts, and use of a better carbon source 
to list a few (Schmid, Sieber, Rehm 2015; Thorne et al. 2000; Zhang et al. 2003). A 
potential caveat to these optimization techniques is that EPS may lose its 
immunomodulatory activity and thus any product should be tested for protective effects. 
 
Analysis of the Properties of EPS Produced by Bacillus subtilis Mutants 
The lack of simple methods for the analysis of polysaccharides has limited 
research. Of the methods currently available for the analysis of polysaccharides, 
combined use of various NMR techniques and mass spectrometry offer the best way to 
study a number of properties including polysaccharide structure and composition (Bubb 
2003; Roux et al. 2015). 
NMR approaches used in this thesis have already proven useful for understanding 
the structure of mutant forms of EPS. The forms of EPS identified enzymatically, and by 
NMR, suggest there are relatively low and varying levels of glucose and mannose in the 
samples of EPS tested. NMR analysis has also proven useful in demonstrating that a 
single long polysaccharide may be present in samples tested. The structure of the 
immunomodulatory carbohydrate, PSA from B. fragilis, was resolved through NMR 
spectroscopy and provided information to show how surface-exposed charges could 
interact with MHCII molecules (Baumann et al. 1992; Cobb et al. 2004; Kalka-Moll et al. 
2002). Although EPS is not currently known to have a charge, elucidation of the structure 
of EPS from various B. subtilis mutants will provide a better understanding of residues 
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present and may help elucidate the roles that enzymes of the epsA-O operon play in 
EPS biosynthesis. 
Analyses by NMR and mass spectrometry will enable closer inspection of the 
composition and types of residues found in samples of EPS and allow for comparison 
between protective and non-protective forms of EPS. Elucidation of the components of 
EPS produced by ΔepsJ, which behaves in a similar manner to WT EPS, shows a high 
degree of similarity to WT EPS. EPS from ΔepsE, which is believed to be protective, and 
ΔepsF, which is not believed to be protective, are ideal for further study. 
While not typically used, pulse chase experiments, using radiolabeled carbon, 
have been used successfully in the past to study bacterial polysaccharide synthesis 
(Robyt, Yoon, Mukerjea 2008). Employing pulse chase methods, the first experiments 
used radiolabeled 14C-sucrose successfully followed the transfer of sucrose molecules to 
the reducing end of a growing dextran polymer. 
 
Concluding Remarks 
In summary, this work has sought to characterize a complex polysaccharide, EPS, 
using strains of B. subtilis with deletions of the genes encoded in the epsA-O operon. 
Through the use of a C. rodentium disease model, 13 genes of the epsA-O operon of B. 
subtilis were identified as being necessary for prevention of inflammatory disease 
induced by the enteric pathogen. Consistent with the idea that B. subtilis can provide 
protection from disease, we isolated and identified B. subtilis in Natto products that also 
protected mice from disease, thus providing a clinical approach towards treatment. 
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Critically, Natto is a product that has been available for decades and is safe for human 
consumption. 
Collectively, these data highlight the complicated nature of bacterial 
polysaccharide biosynthesis, demonstrate that protection is available from commercially 
available sources, and provide a new avenue to study the enzymes needed for protection. 
We can begin compositional studies to examine the similarities and differences of 
protective EPS. Further study should help elucidate and advance the field of carbohydrate 
polymer research, provide a rationale for further study of EPS from epsA-O operon 
mutants, and may aid in identification of other bacterial EPSs with immunomodulatory 
activity. 
While this work has provided a better phenotypic understanding of EPS, the 
immunomodulatory activity, and structural analysis of EPS are needed for a true 
understanding of how these polysaccharides interact with the host. 
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